SGI-110 in Participants With Myelodysplastic Syndromes (M... | NCT01261312 | Trialant
Toggle Sidebar
Studies SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) NCT01261312 Show options Astex Pharmaceuticals, Inc.
Obsolete or Duplicate NCT IDs Not provided
SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
A Phase 1-2, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Astex Pharmaceuticals, Inc. INDUSTRY
Overall Recruitment Status or Expanded Access Status Completed
First Submission Date that Met QC Criteria Dec 15, 2010
Results First Submitted Date May 1, 2023
Results First Submitted that Met QC Criteria Dec 27, 2024
Results First Posted Date Jan 23, 2025 Actual
Certification/Extension (aka Delayed Results) First Submitted Date May 22, 2019
Certification/Extension First Submitted that Passed QC Review May 22, 2019
Certification/Extension First Posted Date May 31, 2019 Actual
Last Update Submitted Date Dec 27, 2024
Responsible Party, by Official Title Sponsor
Astex Pharmaceuticals, Inc. INDUSTRY
Has Data Monitoring Committee (DMC) No
Pediatric Postmarket Surveillance of a Device Product Not provided
Phase 1-2 dose-escalation randomized study in participants with intermediate or high risk myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). The Dose Escalation Segment will evaluate the biological activity, preliminary safety and efficacy of SGI-110 with two dosing schedules in MDS and AML participants while the Dose Expansion Segment will further evaluate safety and efficacy at the biological effective dose (BED) or maximum tolerated dose (MTD) as defined in the Dose Escalation Segment.
Once the biologically effective dose (BED) and maximum tolerated dose (MTD) is determined in the Dose Escalation Segment, the Dose Expansion Segment will randomize participants with MDS, treatment naïve elderly acute myeloid leukemia (AML), and relapsed/refractory AML participants to receive the BED or MTD dose. Relapsed/refractory AML participants may also receive SGI-110 on a daily x 10 schedule based on the total dose per cycle evaluated in the Dose-escalation Segment using the 5-daily regimen.
SGI-110 DNA Hypomethylating Agent Intermediate 1, Intermediate 2, CMML or High Risk MDS AML Number of References to an Expanded Access Study Not provided
Target Follow-Up Duration Not provided
No data available
No data is available for this block.
Label Type Description Intervention Names Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Experimental Participants received starting dose of guadecitabine 3 milligrams per meter square (mg/m^2), subcutaneously (SC), daily from Days 1-5, of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly Experimental Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15, of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly Experimental Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18, of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) Experimental Participants received guadecitabine 60 mg/m^2, SC, daily, from Days 1-5, of a 28-day cycle in participants with diagnosis relapsed/refractory (r/r) AML.
Name Type Description Arm Group Labels Other Names Guadecitabine Drug Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly
Measure Description Time Frame Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
Cycle 1 Day 8 Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
Cycle 1 Day 15 Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
Cycle 1 Day 22 Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
Measure Description Time Frame Dose Escalation Phase: Response Rate in AML Participants Response rate for AML participants was assessed by Modified International Working Group (IWG) 2003 response criteria with complete response (CR), complete response with incomplete platelet recovery (CRp), CR with incomplete blood count recovery(CRi), and partial response (PR). CR: absolute neutrophil count (ANC) >1.0×10^9/L, platelets ≥100×10^9/L, independence from RBC and platelet transfusions, no or <5% myeloblasts in bone marrow(BM). CRp: ANC >1.0×10^9/L, Platelets <100×10^9/L, independence from RBC transfusions, no or <5% myeloblasts in BM. CRi: ANC <1.0×10^9/L, no or <5% myeloblasts in BM. PR: ANC >1.0×10^9/L, Platelets ≥100×10^9/L, no or decrease of ≥50% in myeloblasts to 5-25% in BM.
Inclusion Criteria:
Men or women, 18 years of age or older, with a confirmed diagnosis of international prognostic scoring system (IPSS) intermediate-1, intermediate-2 or high-risk MDS including Chronic Myelomonocytic Leukemia (CMML) or AML.
In the Dose Escalation Segment, participants who are refractory, relapsed, or unresponsive to standard treatment.
In the Dose Expansion Segment, hypomethylating agent (HMA) treatment-naïve MDS participants (including CMML), and intermediate-2 or high-risk MDS participant (including CMML) relapsed or refractory to prior HMA treatment are allowed, and treatment-naïve AML participants who is at least 65 years of age will be allowed if they also have at least one of the following criteria
AML secondary to MDS, chemotherapy, or radiation therapy
poor cytogenetics
pre-existing clinically significant dysfunction of the heart or Chronic Obstructive Pulmonary Disease (COPD)
poor performance status, Eastern Cooperative Oncology Group (ECOG), of 2
Eastern ECOG performance status of 0 to 2.
Adequate organ function.
Prior allogeneic stem cell transplant, no evidence of active graft-versus host disease (GVHD) and must be ≥ 2 weeks off immunosuppressive therapy.
No major surgery within 4 weeks of first dose of SGI-110.
No chemotherapy within 2 weeks of first dose of SGI-110 (minimum of 6 weeks for nitrosoureas and 8 weeks for bone marrow transplantation) with the exception of hydroxyurea which will be allowed during course 1 of treatment.
Sign an approved informed consent form for this study.
Exclusion Criteria:
In the Dose Expansion Segment, which includes the 10-day regimen, participants who have received 2 complete full dose cycles or more of a hypomethylating agent (HMA) decitabine or azacitidine (except for intermediate-2 or high-risk MDS participant (including CMML) relapsed or refractory to prior HMA treatment).
Acute promyelocytic leukemia (M3 classification).
Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the participant has been disease free for at least 3 years.
Life-threatening illnesses other than AML or MDS, uncontrolled medical conditions or organ system dysfunction which, in the investigator's opinion, could compromise the participant's safety, or put the study outcomes at risk.
Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).
Hypersensitivity to decitabine, SGI-110, or SGI-110 excipients.
With the exception of treatment-naïve elderly AML participants, participants with uncontrolled congestive heart failure (CHF), coronary heart disease (CAD), chronic obstructive pulmonary disease (COPD), or left ventricular ejection fraction (LVEF) of ≤ 50% are excluded, symptomatic or uncontrolled arrhythmias or on continuous corticosteroids.
Accepts Healthy Volunteers No
Facility Status City State ZIP Country Contacts Mayo Clinic Scottsdale Arizona 85259 United States University of Southern California
PubMed Identifier Type Citation Retractions Derived Chung W, Kelly AD, Kropf P, Fung H, Jelinek J, Su XY, Roboz GJ, Kantarjian HM, Azab M, Issa JJ. Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. Clin Epigenetics. 2019 Jul 22;11(1):106. doi: 10.1186/s13148-019-0704-3. Derived Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. Lancet Haematol. 2019 Jun;6(6):e317-e327. doi: 10.1016/S2352-3026(19)30029-8. Epub 2019 May 3.
Available IPD Information Not provided
No data available
No data is available for this block.
Total 94 participants with Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) were enrolled in Dose escalation Phase 1, out of which 93 received treatment; Total 108 participants with relapsed and refractory (r/r) AML were enrolled, and 103 received study treatment; 107 participants with TN AML were enrolled, and 103 participants received study treatment; 105 participants with MDS were enrolled, and 102 received study treatment in Dose expansion (DE) Phase 2.
ID Title Description FG000 Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Participants received starting dose of guadecitabine 3 milligrams per meter square (mg/m^2), subcutaneously (SC), daily from Days 1-5 of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Title Milestones Reasons Not Completed Dose Escalation Phase (Day 0- Week 170) Type Comment Milestone Data STARTED
Baseline Analysis Population Description
No data available
No data is available for this block.
No data available
No data is available for this block.
No data available
No data is available for this block.
No data available
No data is available for this block.
Randomized
Intervention Model Description Not provided
Drug: Guadecitabine Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) Experimental Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5, of a 28-day cycle in participants with a diagnosis of r/r AML.
Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) Experimental Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5 and 8-12, of a 28-day cycle in participants with a diagnosis of r/r AML.
Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) Experimental Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5, SC of a 28-day cycle in participants with a diagnosis of treatment naïve (TN) AML.
Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) Experimental Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5, of a 28-day cycle in participants with a diagnosis of TN AML.
Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) Experimental Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5 and 8-12, of a 28-day cycle in participants with a diagnosis of TN AML.
Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) Experimental Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5, of a 28-day cycle in participants with a diagnosis of r/r Myelodysplastic Syndromes (MDS).
Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) Experimental Participants received guadecitabine 90 mg/m^2, SC, daily on Days 1-5, of a 28-day cycle in participants with a diagnosis of r/r MDS.
Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) Experimental Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5, of a 28-day cycle in participants with a diagnosis of TN MDS.
Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) Experimental Participants received guadecitabine 90 mg/m^2, SC daily on Days 1-5, of a 28-day cycle in participants with a diagnosis of TN MDS.
Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly
Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day)
Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day)
Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day)
Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day)
Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day)
Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day)
Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day)
Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day)
Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day)
Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) Dose Escalation Phase-Maximum Tolerated Dose (MTD): Number of Participants With Dose Limiting Toxicity (DLT) The MTD was defined as the largest dose for which less than 33% of subjects experienced a dose limiting toxicity (DLT) during Cycle 1 of guadecitabine administration at each dose level. DLTs were defined using the Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0).
From the start of study treatment up to 30 days post treatment (Up to approximately 46 months)
Dose Expansion (DE) Phase- r/r AML, TN AML: Composite Complete Response (CRc) Rate Composite complete response (CRc) rate is defined as the percentage of participants whose best response is complete remission [CR], CR with incomplete platelet recovery [CRp], or CR with incomplete hematological recovery [CRi]) after treatment with study drug. CR as per AML response criteria is defined as peripheral blood absolute neutrophil count (ANC) ≥1.0×10^9/L, Platelets ≥100×10^9/L, independence from red blood cell (RBC) and platelet transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRp as per AML response criteria is defined as peripheral blood ANC ≥1.0×10^9/L, Platelets <100×10^9/L, independence from RBC transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRi as per AML response criteria is defined as peripheral blood ANC <1.0×10^9/L, no myeloblasts and <5% myeloblasts in bone marrow.
At end of each Cycle of 28 days (Up to approximately 38 months)
Dose Expansion (DE) Phase- r/r MDS, TN MDS: Overall Response Rate (ORR) ORR is defined as percentage of participants with complete response(CR), partial response(PR), marrow complete response(mCR) and haematological improvement(HI). CR:normal peripheral counts with persistent granulocyte count ≥1.0×10^9/L, platelet count ≥100×10^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. PR:normal peripheral counts with granulocyte count ≥1.0×10^9/L and platelet count ≥100 ×10^9/L and normal BM with marrow blasts >5% but were reduced by 50% or more. mCR:reduction of BM blasts to ≤5% without normalization of peripheral counts. HI is divided as erythroid response(HI-E): hemoglobin increase ≥1.5 g/dL or red blood cells transfusion independence, platelet response (HI-P): absolute increase of platelet count from <20 to >20×10^9/L and by at least 100%,/if more than 20×10^9/L, by an absolute increase of 30×10^9/L, neutrophil response (HI-N): granulocyte increase ≥100%, and by an absolute increase ≥0.5×10^9/L.
At end of each Cycle of 28 days (Up to approximately 45 months)
At end of each Cycle of 28 days (Up to approximately 23 months)
Dose Escalation Phase: Response Rate in MDS Participants Response rate for MDS participants was assessed by IWG 2006 Response Criteria with CR, PR, marrow complete response(mCR) and HI. CR: normal peripheral counts with persistent granulocyte count ≥1.0×10^9/L, platelet count ≥100×10^9/L; normal BM with persistent marrow blasts ≤5%; persistent dysplasia. PR: Normal peripheral counts with granulocyte count ≥1.0×10^9/L, platelet count ≥100×10^9/L and normal BM with blasts >5% but reduced by 50% or more. mCR: reduction of BM blasts to ≤5% without normalization of peripheral counts.
At end of each Cycle of 28 days (Up to approximately 23 months)
Dose Escalation and Dose Expansion Phase- r/r AML, TN AML: Duration of Response Duration of response (in number of days) was calculated from the first time a complete response (CR, CRp, or CRi) was observed to time of relapse defined as the earliest time point whereby BM blasts or peripheral blood blasts become ≥5% and stayed at that level in subsequent visits while participants were still on study. CR:normal peripheral counts with persistent granulocyte count ≥1.0×10^9/L, platelet count ≥100×10^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. CRp as per AML response criteria is defined as peripheral blood ANC ≥1.0×10^9/L, Platelets <100×10^9/L, independence from RBC transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRi as per AML response criteria is defined as peripheral blood ANC <1.0×10^9/L, no myeloblasts and <5% myeloblasts in bone marrow.
At end of each Cycle of 28 days (Up to approximately 38 months)
Dose Escalation Phase: Hematologic Improvement Rate in MDS At end of each Cycle of 28 days (Up to approximately 45 months)
DE Phase- r/r MDS, TN MDS: Duration of Response DOR was calculated from first time a response category (CR, PR, mCR, or HI) was achieved until response category was no longer met or the last available time point, whichever occurred first. CR:normal peripheral counts with persistent granulocyte count ≥1.0×10^9/L, platelet count ≥100×10^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. PR:normal peripheral counts with granulocyte count ≥1.0×10^9/L and platelet count ≥100 ×10^9/L and normal BM with marrow blasts >5% but were reduced by 50% or more. mCR:reduction of BM blasts to ≤5% without normalization of peripheral counts. HI is divided as erythroid response(HI-E): hemoglobin increase ≥1.5 g/dL or RBC transfusion independence, platelet response (HI-P): absolute increase of platelet count from <20 to >20×10^9/L by at least 100%,/if more than 20×10^9/L, by absolute increase of 30×10^9/L, neutrophil response (HI-N): granulocyte increase ≥100%, by an absolute increase ≥0.5×10^9/L.
At end of each Cycle of 28 days (Up to approximately 45 months)
Dose Escalation r/r AML, TN AML: Time to Response Time to response was defined as the number of days from the day a participants received the first dose of guadecitabine (cycle 1 day 1 {C1D1}) to the first day of response. Composite complete response rate (CRc = CR + CRp + CRi), which is an overall complete response assessment including CR, CR with incomplete platelet recovery (CRp) and CR with incomplete blood count recovery (CRi). CRc rate, was defined as the number of participants who achieved a response status of CR, CRp, or CRi divided by the total number of participants included in the efficacy dataset. The CR rate is defined as the number of participants whose best response is CR divided by the total number of participants included in the efficacy dataset.
At end of each Cycle of 28 days (Up to approximately 38 months)
Dose Expansion Phase- r/r MDS, TN MDS: Time to Response Time to response was defined as the number of days from the day a participants received the first dose of guadecitabine (C1D1) to the first day of response. CR:normal peripheral counts with persistent granulocyte count ≥1.0×10^9/L, platelet count ≥100×10^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. PR:normal peripheral counts with granulocyte count ≥1.0×10^9/L and platelet count ≥100 ×10^9/L and normal BM with marrow blasts >5% but were reduced by 50% or more. mCR:reduction of BM blasts to ≤5% without normalization of peripheral counts. HI is divided as erythroid response(HI-E): hemoglobin increase ≥1.5 g/dL or RBC transfusion independence, platelet response (HI-P): absolute increase of platelet count from <20 to >20×10^9/L by at least 100%,/if more than 20×10^9/L, by absolute increase of 30×10^9/L, neutrophil response (HI-N): granulocyte increase ≥100%, by an absolute increase ≥0.5×10^9/L.
At end of each Cycle of 28 days (Up to approximately 45 months)
Number of Participants With Dose Limiting Toxicities (DLT) Assessed Per Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 DLT was defined using CTCAE v4.0. Toxicities were considered related to SGI-110 if it cannot be explained by underlying disease, intercurrent illness or concomitant medications. Any related Grade 3 or 4 non-hematologic toxicity except Grade 3 or 4 nausea/vomiting that is controllable by anti-emetics or diarrhea controllable by optimal therapy. Grade 3 laboratory investigations other than serum creatinine, bilirubin, AST or ALT were not considered a DLT unless they are associated with clinical manifestations. Study-drug related Grade 4 thrombocytopenia and Febrile neutropenia that was not present at study entry, and not resolve within 7 days, and is not related to underlying disease. Prolonged myelosuppression or pancytopenia with hypocellular bone marrow and no marrow blasts lasting for 6 weeks or more that is not related to disease progression. Any toxicity that results in treatment delays of > 4 weeks. Data is reported for any AE occurring during Cycle 1 (each cycle = 28 days).
Cycle 1 (each cycle = 28 days)
Dose Escalation and Dose Expansion Phases- r/r AML, TN AML, r/r MDS, TN MDS: Number of Participants With At Least One Treatment-Emergent Adverse Events (TEAEs) Treatment-emergent AEs are defined as events that first occurred or worsened after the first dose of study drug given on C1D1 until 30 days after the last dose of study treatment or the start of an alternative anti-cancer treatment for MDS/CMML and subsequent AML, whichever occurs first, with the following exceptions: events that occurred after 30 days beyond the last dose of study treatment or the start of an alternative anti-cancer treatment for MDS/CMML and subsequent AML was considered treatment-emergent if the events are both serious and related to the study treatment.
From first dose of study drug up 30 days post treatment (up to approximately 46 months)
Dose Escalation and DE Phases- r/r AML, TN AML, r/r MDS, TN MDS: Number of Participants With Abnormal Laboratory Values Reported as Adverse Events From first dose of study drug up 30 days post treatment (up to approximately 46 months)
Dose Escalation: Maximum Observed Plasma Concentration (Cmax ) of SGI-110 and Decitabine Days 1, 5 and 8
Dose Escalation: Minimum Observed Plasma Concentration (Cmin) Days 5 and 8
Dose Escalation: Area Under the Curve to Infinity (AUC0-inf) Days 1, 5 and 8
Dose Escalation and DE Phase- r/r MDS, TN MDS: Time to AML or Death Time to AML or death was defined as the number of days from the date the subject received the first dose of guadecitabine (C1D1) to the date of death or the date of MDS/ chronic myelomonocytic leukemia (CMML) progression to AML, whichever occurred earlier. Time to AML or death was evaluated using the Kaplan-Meier method, with the time censored on the last date of contact if a participant was still alive without progression to AML.
At end of each Cycle of 28 days (Up to approximately 38 months)
Dose Escalation and DE Phases- r/r AML, TN AML, r/r MDS, TN MDS: Overall Survival OS was defined as the number of days from the day the participant received the first dose of guadecitabine to the date of death (regardless of cause).
At end of each Cycle of 28 days (Up to approximately 45 months)
Dose Escalation: Number of Participants Achieving Blood and Platelet Transfusions Cycle 1, Day 1 through 30 days after the last dose of study drug (up to approximately 46 months)
DE Phase- r/r AML, TN AML: Percentage of Participants With Cr, CRp and PR CR is defined absolute neutrophil count (ANC) >1.0×109/L, Platelets ≥100×109/L, independence from RBC and platelet transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRp is defined ANC >1.0×10^9/L, Platelets <100×10^9/L, independence from RBC transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRi is defined as ANC <1.0×10^9/L, no myeloblasts and <5% myeloblasts in bone marrow. PR is defined as ANC >1.0×10^9/L, Platelets ≥100×10^9/L, no myeloblasts and Decrease of ≥50% in myeloblasts to level of 5% to 25% in bone marrow.
At end of each Cycle of 28 days (Up to approximately 45 months)
DE Phase- r/r MDS, TN MDS: Percentage of Participants With CR, PR, mCR and HI CR is defined ANC >1.0×109/L, Platelets ≥100×109/L, independence from RBC and platelet transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRp is defined ANC >1.0×10^9/L, Platelets <100×10^9/L, independence from RBC transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRi is defined as ANC <1.0×10^9/L, no myeloblasts and <5% myeloblasts in bone marrow. PR is defined as ANC >1.0×10^9/L, Platelets ≥100×10^9/L, no myeloblasts and Decrease of ≥50% in myeloblasts to level of 5% to 25% in bone marrow.
At end of each Cycle of 28 days (Up to approximately 45 months)
DE Phase- r/r MDS, TN MDS: Number of Participants Achieving Blood Transfusion Independence for 8 or 16-weeks Transfusion dependence at baseline was defined as any transfusion within 4 weeks of the first study dose (C1D1) with C1D1 transfusion counted, assuming it was always done before dosing. Transfusion independence after treatment was defined as no transfusion within an 8-week or 16-week period between C1D1 and last treatment date + 30 days.
Weeks 8 and 16
DE Phase- r/r MDS, TN MDS: Number of Participants Achieving Platelet Transfusion Independence for 8 or 16-weeks Transfusion dependence at baseline was defined as any transfusion within 4 weeks of the first study dose (C1D1) with C1D1 transfusion counted, assuming it was always done before dosing. Transfusion independence after treatment was defined as no transfusion within an 8-week or 16-week period between C1D1 and last treatment date + 30 days.
Weeks 8 and 16
Yale University New Haven Connecticut 06520 United States
Florida Cancer Specialists - South Fort Myers Florida 33916 United States
Florida Cancer Specialists - North St. Petersburg Florida 33705 United States
University of Chicago Cancer Center Chicago Illinois 60637 United States
Roswell Park Cancer Institute Buffalo New York 14263 United States
Cornell University New York New York 10021 United States
Columbia University Medical Center New York New York 10032 United States
Duke University Durham North Carolina 27705 United States
Ohio State University Columbus Ohio 43210 United States
Temple University Philadelphia Pennsylvania 19111 United States
Sarah Cannon Research Institute Nashville Tennessee 37203 United States
Tennessee Oncology Nashville Tennessee 37203 United States
MD Anderson Cancer Center Houston Texas 77030 United States
Princess Margaret Hospital Toronto Ontario M5G 2M9 Canada
Derived Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep;16(9):1099-1110. doi: 10.1016/S1470-2045(15)00038-8. Epub 2015 Aug 19.
Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly
Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15 of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
FG002 Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18 of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
FG003 Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily,from Days 1-5 of a 28-day cycle in participants with diagnosis of relapsed/refractory (r/r) AML.
FG004 Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5of a 28-day cycle in participants with a diagnosis of r/r AML.
FG005 Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5 and 8-12of a 28-day cycle in participants with a diagnosis of r/r AML.
FG006 Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, dailyfrom Days 1-5, SC of a 28-day cycle in participants with a diagnosis of treatment naïve (TN) AML.
FG007 Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5of a 28-day cycle in participants with a diagnosis of TN AML.
FG008 Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) Participants received guadecitabine 60 mg/m^2, SC, daily, from Days 1-5 and 8-12of a 28-day cycle in participants with a diagnosis of TN AML.
FG009 Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of r/r Myelodysplastic Syndromes (MDS).
FG010 Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily on Days 1-5of a 28-day cycle in participants with a diagnosis of r/r MDS.
FG011 Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
FG012 Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC. daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
FG000 44 subjects FG001 35 subjects FG002 15 subjects FG003 0 subjects FG004 0 subjects FG005 0 subjects FG006 0 subjects FG007 0 subjects FG008 0 subjects FG009 0 subjects FG010 0 subjects FG011 0 subjects FG012 0 subjects Safety Data Set Participants who received at least one dose of study treatment were included in safety data set.
FG000 44 subjects FG001 34 subjects FG002 15 subjects FG003 0 subjects FG004 0 subjects FG005 0 subjects FG006 0 subjects FG007 0 subjects FG008 0 subjects FG009 0 subjects FG010 0 subjects FG011 0 subjects FG012 0 subjects
COMPLETED FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004 0 subjects FG005 0 subjects FG006 0 subjects FG007 0 subjects FG008 0 subjects FG009 0 subjects FG010 0 subjects FG011 0 subjects FG012 0 subjects
NOT COMPLETED FG000 44 subjects FG001 35 subjects FG002 15 subjects FG003 0 subjects FG004 0 subjects FG005 0 subjects FG006 0 subjects FG007 0 subjects FG008 0 subjects FG009 0 subjects FG010 0 subjects FG011 0 subjects FG012 0 subjects
Type Comment Reasons Progressive Disease FG000 27 subjects FG001 26 subjects FG002 9 subjects FG003 0 subjects FG004 0 subjects FG005 0 subjects FG006 0 subjects FG007 0 subjects FG008 0 subjects FG009 0 subjects FG010 0 subjects FG011 0 subjects FG012 0 subjects Adverse Event FG000 1 subjects FG001 1 subjects FG002 0 subjects FG003 0 subjects FG004 Subject Withdrew Consent FG000 3 subjects FG001 2 subjects FG002 0 subjects FG003 0 subjects FG004 Death FG000 5 subjects FG001 4 subjects FG002 0 subjects FG003 0 subjects FG004 Investigator Decision FG000 4 subjects FG001 1 subjects FG002 3 subjects FG003 0 subjects FG004 Hematopoietic Cell Transplant (HCT) FG000 1 subjects FG001 1 subjects FG002 1 subjects FG003 0 subjects FG004 Reason not Specified FG000 3 subjects FG001 0 subjects FG002 2 subjects FG003 0 subjects FG004
DE Phase: r/r AML (Week 75-242) Type Comment Milestone Data STARTED FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 25 subjects FG004 28 subjects FG005 55 subjects FG006 0 subjects FG007 0 subjects FG008 0 subjects FG009 0 subjects FG010 0 subjects FG011 0 subjects FG012 0 subjects Safety Data Set Participants who received at least one dose of study treatment were included in safety data set.
FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 COMPLETED FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 1 subjects FG004 NOT COMPLETED FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 24 subjects FG004
Type Comment Reasons Progressive Disease FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003
DE Phase: TN AML (Week 85-283) Type Comment Milestone Data STARTED FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004 0 subjects FG005 0 subjects FG006 26 subjects FG007 28 subjects FG008 53 subjects FG009 0 subjects FG010 0 subjects FG011 0 subjects FG012 0 subjects Safety Data Set Participants who received at least one dose of study treatment were included in safety data set.
FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 COMPLETED FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004 NOT COMPLETED FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004
Type Comment Reasons Progressive Disease FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003
DE Phase: r/r MDS &TN MDS (Week 78-298) Type Comment Milestone Data STARTED FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004 0 subjects FG005 0 subjects FG006 0 subjects FG007 0 subjects FG008 0 subjects FG009 27 subjects FG010 27 subjects FG011 28 subjects FG012 23 subjects Safety Data Set Participants who received at least one dose of study treatment were included in safety data set.
FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 COMPLETED FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004 NOT COMPLETED FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004
Type Comment Reasons Progressive Disease FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003
Efficacy data set included all participants who received at least one dose of study drug.
ID Title Description BG000 Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Participants received starting dose of guadecitabine 3 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
BG001 Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
BG002 Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
BG003 Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily,from Days 1-5 of a 28-day cycle in participants with diagnosis of r/r AML.
BG004 Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5of a 28-day cycle in participants with a diagnosis of r/r AML.
BG005 Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5 and 8-12of a 28-day cycle in participants with a diagnosis of r/r AML.
BG006 Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5, SC of a 28-day cycle in participants with a diagnosis of TN AML.
BG007 Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5of a 28-day cycle in participants with a diagnosis of TN AML.
BG008 Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) Participants received guadecitabine 60 mg/m^2, SC, daily, from Days 1-5 and 8-12of a 28-day cycle in participants with a diagnosis of TN AML.
BG009 Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of r/r MDS.
BG010 Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily on Days 1-5of a 28-day cycle in participants with a diagnosis of r/r MDS.
BG011 Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
BG012 Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC. daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
BG013 Total Total of all reporting groups
Units Counts Participants BG000 44 BG001 34 BG002 15 BG003 24 BG004 26 BG005 53 BG006 24 BG007 27 BG008 52 BG009 26 BG010 27 BG011 27 BG012 22 BG013 401
Title Description Population Description Parameter Type Dispersion Type Unit of Measure Calculate Percentage Denominator Units Selected Denominators Classes Age, Continuous Mean Full Range years Title Denominators Categories Title Measurements BG000 66.22 (36.7 to 86.1) BG001 64.90 (29.1 to 83.4) BG002 71.04 (51.4 to 84.6) BG003
Sex: Female, Male Count of Participants Participants Title Denominators Categories
Ethnicity (NIH/OMB) Count of Participants Participants Title Denominators Categories Title Measurements Hispanic or Latino
Race (NIH/OMB) Count of Participants Participants Title Denominators Categories Title Measurements American Indian or Alaska Native
Type Title Description Population Description Reporting Status Anticipated Posting Date Parameter Type Dispersion Type Unit of Measure Calculate Percentage Time Frame Units Analyzed Denominator Units Selected Arm/Group Information Denominators Classes Analyses Primary Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
Pharmacodynamic (PD) analysis set included all participants who provided evaluable blood samples for analysis of at least one PD parameter or biomarker being tested. Overall number analyzed is number of participants with data available for analysis.
Posted Mean Standard Deviation percent change Cycle 1 Day 8 ID Title Description OG000 Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Participants received starting dose of guadecitabine 3 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG001 Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG002 Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Title Denominators Categories Title Measurements OG000 -16.143 ± 12.692 OG001 -4.362 ± 5.484 OG002 -10.574 ± 8.444
Primary Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
Pharmacodynamic (PD) analysis set included all participants who provided evaluable blood samples for analysis of at least one PD parameter or biomarker being tested. Overall number analyzed is number of participants with data available for analysis.
Posted Mean Standard Deviation percent change Cycle 1 Day 15 ID Title Description OG000 Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Participants received starting dose of guadecitabine 3 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG001 Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Primary Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
Pharmacodynamic (PD) analysis set included all participants who provided evaluable blood samples for analysis of at least one PD parameter or biomarker being tested. Overall number analyzed is number of participants with data available for analysis.
Posted Mean Standard Deviation percent change Cycle 1 Day 22 ID Title Description OG000 Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Participants received starting dose of guadecitabine 3 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG001 Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Primary Dose Escalation Phase- Biological Effective Dose (BED): Percent Change From Baseline in DNA Long Interspersed Nucleotide Element-1 (LINE-1) Demethylation DNA LINE-1 demethylation is defined as the largest percent decrease from baseline in methylation values within a participant between Day 8 and Day 22 of the first treatment cycle. BED was assessed based on DNA LINE-1 demethylation results and defined as the smallest dose that achieves the maximum biological pharmacodynamic (PD) effect (LINE-1 demethylation) in at least 3 successive dose levels.
Pharmacodynamic (PD) analysis set included all participants who provided evaluable blood samples for analysis of at least one PD parameter or biomarker being tested. Overall number analyzed is number of participants with data available for analysis.
Posted Mean Standard Deviation percent change Cycle 2 Day 1 ID Title Description OG000 Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Participants received starting dose of guadecitabine 3 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG001 Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Primary Dose Escalation Phase-Maximum Tolerated Dose (MTD): Number of Participants With Dose Limiting Toxicity (DLT) The MTD was defined as the largest dose for which less than 33% of subjects experienced a dose limiting toxicity (DLT) during Cycle 1 of guadecitabine administration at each dose level. DLTs were defined using the Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0).
Safety data analysis set included all regimen 1, 2A and 2 B participants who received at least one dose of study drug.
Posted Count of Participants Participants From the start of study treatment up to 30 days post treatment (Up to approximately 46 months) ID Title Description OG000 Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Participants received starting dose of guadecitabine 3 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG001 Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG002
Primary Dose Expansion (DE) Phase- r/r AML, TN AML: Composite Complete Response (CRc) Rate Composite complete response (CRc) rate is defined as the percentage of participants whose best response is complete remission [CR], CR with incomplete platelet recovery [CRp], or CR with incomplete hematological recovery [CRi]) after treatment with study drug. CR as per AML response criteria is defined as peripheral blood absolute neutrophil count (ANC) ≥1.0×10^9/L, Platelets ≥100×10^9/L, independence from red blood cell (RBC) and platelet transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRp as per AML response criteria is defined as peripheral blood ANC ≥1.0×10^9/L, Platelets <100×10^9/L, independence from RBC transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRi as per AML response criteria is defined as peripheral blood ANC <1.0×10^9/L, no myeloblasts and <5% myeloblasts in bone marrow.
Efficacy analysis set included r/r AML and TN AML participants who received at least one dose of study drug.
Posted Number 95% Confidence Interval percentage of participants At end of each Cycle of 28 days (Up to approximately 38 months) ID Title Description OG000 Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily, from Days 1-5 of a 28-day cycle in participants with diagnosis of r/r AML.
OG001 Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day)
Primary Dose Expansion (DE) Phase- r/r MDS, TN MDS: Overall Response Rate (ORR) ORR is defined as percentage of participants with complete response(CR), partial response(PR), marrow complete response(mCR) and haematological improvement(HI). CR:normal peripheral counts with persistent granulocyte count ≥1.0×10^9/L, platelet count ≥100×10^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. PR:normal peripheral counts with granulocyte count ≥1.0×10^9/L and platelet count ≥100 ×10^9/L and normal BM with marrow blasts >5% but were reduced by 50% or more. mCR:reduction of BM blasts to ≤5% without normalization of peripheral counts. HI is divided as erythroid response(HI-E): hemoglobin increase ≥1.5 g/dL or red blood cells transfusion independence, platelet response (HI-P): absolute increase of platelet count from <20 to >20×10^9/L and by at least 100%,/if more than 20×10^9/L, by an absolute increase of 30×10^9/L, neutrophil response (HI-N): granulocyte increase ≥100%, and by an absolute increase ≥0.5×10^9/L.
Efficacy analysis set included r/r MDS and TN MDS participants who received at least one dose of study drug.
Posted Number 95% Confidence Interval percentage of participants At end of each Cycle of 28 days (Up to approximately 45 months) ID Title Description OG000 Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of r/r MDS.
OG001 Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day)
Secondary Dose Escalation Phase: Response Rate in AML Participants Response rate for AML participants was assessed by Modified International Working Group (IWG) 2003 response criteria with complete response (CR), complete response with incomplete platelet recovery (CRp), CR with incomplete blood count recovery(CRi), and partial response (PR). CR: absolute neutrophil count (ANC) >1.0×10^9/L, platelets ≥100×10^9/L, independence from RBC and platelet transfusions, no or <5% myeloblasts in bone marrow(BM). CRp: ANC >1.0×10^9/L, Platelets <100×10^9/L, independence from RBC transfusions, no or <5% myeloblasts in BM. CRi: ANC <1.0×10^9/L, no or <5% myeloblasts in BM. PR: ANC >1.0×10^9/L, Platelets ≥100×10^9/L, no or decrease of ≥50% in myeloblasts to 5-25% in BM.
Efficacy analysis set included regimen 1, 2A and 2B participants who received at least one dose of study drug. Overall number of participants analyzed are the number of participants with AML available for analysis.
Posted Number 95% Confidence Interval percentage of participants At end of each Cycle of 28 days (Up to approximately 23 months) ID Title Description OG000 Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Participants received starting dose of guadecitabine 3 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG001 Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly
Secondary Dose Escalation Phase: Response Rate in MDS Participants Response rate for MDS participants was assessed by IWG 2006 Response Criteria with CR, PR, marrow complete response(mCR) and HI. CR: normal peripheral counts with persistent granulocyte count ≥1.0×10^9/L, platelet count ≥100×10^9/L; normal BM with persistent marrow blasts ≤5%; persistent dysplasia. PR: Normal peripheral counts with granulocyte count ≥1.0×10^9/L, platelet count ≥100×10^9/L and normal BM with blasts >5% but reduced by 50% or more. mCR: reduction of BM blasts to ≤5% without normalization of peripheral counts.
Efficacy analysis set included regimen 1, 2A and 2B participants who received at least one dose of study drug. Overall number of participants analyzed are the number of participants with MDS available for analysis.
Posted Number 95% Confidence Interval percentage of participants At end of each Cycle of 28 days (Up to approximately 23 months) ID Title Description OG000 Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Participants received starting dose of guadecitabine 3 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG001 Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Secondary Dose Escalation and Dose Expansion Phase- r/r AML, TN AML: Duration of Response Duration of response (in number of days) was calculated from the first time a complete response (CR, CRp, or CRi) was observed to time of relapse defined as the earliest time point whereby BM blasts or peripheral blood blasts become ≥5% and stayed at that level in subsequent visits while participants were still on study. CR:normal peripheral counts with persistent granulocyte count ≥1.0×10^9/L, platelet count ≥100×10^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. CRp as per AML response criteria is defined as peripheral blood ANC ≥1.0×10^9/L, Platelets <100×10^9/L, independence from RBC transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRi as per AML response criteria is defined as peripheral blood ANC <1.0×10^9/L, no myeloblasts and <5% myeloblasts in bone marrow.
Efficacy analysis set included regimen 1, 2A and 2B, r/r AML and TN AML participants who received at least one dose of study drug. Data for responders was reported for this outcome measure.
Posted Median Full Range days At end of each Cycle of 28 days (Up to approximately 38 months) ID Title Description OG000 Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Participants received starting dose of guadecitabine 3 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG001
Secondary Dose Escalation Phase: Hematologic Improvement Rate in MDS Efficacy analysis set included regimen 1, 2A and 2B participants who received at least one dose of study drug. Overall number of participants analyzed are the number of participants with data available for analysis.
Posted Number 95% Confidence Interval percentage of participants At end of each Cycle of 28 days (Up to approximately 45 months) ID Title Description OG000 Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Participants received starting dose of guadecitabine 3 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG001 Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG002 Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Secondary DE Phase- r/r MDS, TN MDS: Duration of Response DOR was calculated from first time a response category (CR, PR, mCR, or HI) was achieved until response category was no longer met or the last available time point, whichever occurred first. CR:normal peripheral counts with persistent granulocyte count ≥1.0×10^9/L, platelet count ≥100×10^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. PR:normal peripheral counts with granulocyte count ≥1.0×10^9/L and platelet count ≥100 ×10^9/L and normal BM with marrow blasts >5% but were reduced by 50% or more. mCR:reduction of BM blasts to ≤5% without normalization of peripheral counts. HI is divided as erythroid response(HI-E): hemoglobin increase ≥1.5 g/dL or RBC transfusion independence, platelet response (HI-P): absolute increase of platelet count from <20 to >20×10^9/L by at least 100%,/if more than 20×10^9/L, by absolute increase of 30×10^9/L, neutrophil response (HI-N): granulocyte increase ≥100%, by an absolute increase ≥0.5×10^9/L.
Efficacy analysis set included participants with MDS who received at least one dose of study drug. Overall number of participants analyzed are the number of participants with response. Number analyzed are the number of participants with data available for analysis.
Posted Median Full Range days At end of each Cycle of 28 days (Up to approximately 45 months) ID Title Description OG000 Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of r/r MDS.
Secondary Dose Escalation r/r AML, TN AML: Time to Response Time to response was defined as the number of days from the day a participants received the first dose of guadecitabine (cycle 1 day 1 {C1D1}) to the first day of response. Composite complete response rate (CRc = CR + CRp + CRi), which is an overall complete response assessment including CR, CR with incomplete platelet recovery (CRp) and CR with incomplete blood count recovery (CRi). CRc rate, was defined as the number of participants who achieved a response status of CR, CRp, or CRi divided by the total number of participants included in the efficacy dataset. The CR rate is defined as the number of participants whose best response is CR divided by the total number of participants included in the efficacy dataset.
Efficacy analysis set included regimen 1, 2A and 2B, r/r AML and TN AML participants who received at least one dose of study drug. Data is reported for responders in this outcome measure.
Posted Median Full Range days At end of each Cycle of 28 days (Up to approximately 38 months) ID Title Description OG000 Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Participants received starting dose of guadecitabine 3 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG001 Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly
Secondary Dose Expansion Phase- r/r MDS, TN MDS: Time to Response Time to response was defined as the number of days from the day a participants received the first dose of guadecitabine (C1D1) to the first day of response. CR:normal peripheral counts with persistent granulocyte count ≥1.0×10^9/L, platelet count ≥100×10^9/L and normal bone marrow (BM) with persistent marrow blasts ≤5%; persistent dysplasia was noted. PR:normal peripheral counts with granulocyte count ≥1.0×10^9/L and platelet count ≥100 ×10^9/L and normal BM with marrow blasts >5% but were reduced by 50% or more. mCR:reduction of BM blasts to ≤5% without normalization of peripheral counts. HI is divided as erythroid response(HI-E): hemoglobin increase ≥1.5 g/dL or RBC transfusion independence, platelet response (HI-P): absolute increase of platelet count from <20 to >20×10^9/L by at least 100%,/if more than 20×10^9/L, by absolute increase of 30×10^9/L, neutrophil response (HI-N): granulocyte increase ≥100%, by an absolute increase ≥0.5×10^9/L.
Efficacy analysis set included r/r MDS and TN MDS participants who received at least one dose of study drug. Overall number of participants analysed are the participants with response. Number analyzed is number of participants with response.
Posted Median Full Range days At end of each Cycle of 28 days (Up to approximately 45 months) ID Title Description OG000 Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of r/r MDS.
OG001
Secondary Number of Participants With Dose Limiting Toxicities (DLT) Assessed Per Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 DLT was defined using CTCAE v4.0. Toxicities were considered related to SGI-110 if it cannot be explained by underlying disease, intercurrent illness or concomitant medications. Any related Grade 3 or 4 non-hematologic toxicity except Grade 3 or 4 nausea/vomiting that is controllable by anti-emetics or diarrhea controllable by optimal therapy. Grade 3 laboratory investigations other than serum creatinine, bilirubin, AST or ALT were not considered a DLT unless they are associated with clinical manifestations. Study-drug related Grade 4 thrombocytopenia and Febrile neutropenia that was not present at study entry, and not resolve within 7 days, and is not related to underlying disease. Prolonged myelosuppression or pancytopenia with hypocellular bone marrow and no marrow blasts lasting for 6 weeks or more that is not related to disease progression. Any toxicity that results in treatment delays of > 4 weeks. Data is reported for any AE occurring during Cycle 1 (each cycle = 28 days).
Safety analysis set included data from regimen 1, 2A and 2B participants who received at least one dose of study drug.
Posted Count of Participants Participants Cycle 1 (each cycle = 28 days) ID Title Description OG000 Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Participants received starting dose of guadecitabine 3 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Secondary Dose Escalation and Dose Expansion Phases- r/r AML, TN AML, r/r MDS, TN MDS: Number of Participants With At Least One Treatment-Emergent Adverse Events (TEAEs) Treatment-emergent AEs are defined as events that first occurred or worsened after the first dose of study drug given on C1D1 until 30 days after the last dose of study treatment or the start of an alternative anti-cancer treatment for MDS/CMML and subsequent AML, whichever occurs first, with the following exceptions: events that occurred after 30 days beyond the last dose of study treatment or the start of an alternative anti-cancer treatment for MDS/CMML and subsequent AML was considered treatment-emergent if the events are both serious and related to the study treatment.
Safety data set included all participants who received at least one dose of study drug.
Posted Count of Participants Participants From first dose of study drug up 30 days post treatment (up to approximately 46 months) ID Title Description OG000 Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Participants received starting dose of guadecitabine 3 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG001 Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Secondary Dose Escalation and DE Phases- r/r AML, TN AML, r/r MDS, TN MDS: Number of Participants With Abnormal Laboratory Values Reported as Adverse Events Safety data set included all participants who received at least one dose of study drug.
Posted Count of Participants Participants From first dose of study drug up 30 days post treatment (up to approximately 46 months) ID Title Description OG000 Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Participants received starting dose of guadecitabine 3 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG001 Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15, SC of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG002 Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Secondary Dose Escalation: Maximum Observed Plasma Concentration (Cmax ) of SGI-110 and Decitabine Pharmacokinetic (PK) analysis set included all available plasma concentrations and PK parameters for guadecitabine and decitabine for participants who received study drug. Number analyzed are the number of participants with data available for analysis at the given timepoint.
Posted Geometric Mean Geometric Coefficient of Variation ng/mL Days 1, 5 and 8 ID Title Description OG000 Dose Escalation: Regimen 1: Once Daily - 3 mg/m^2 Participants received starting dose of guadecitabine 3 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG001 Dose Escalation: Regimen 1: Once Daily - 9 mg/m^2 Participants received starting dose of guadecitabine 9 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG002 Dose Escalation: Regimen 1: Once Daily - 18 mg/m^2 Participants received starting dose of guadecitabine 18 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG003 Dose Escalation: Regimen 1: Once Daily - 36 mg/m^2
Secondary Dose Escalation: Minimum Observed Plasma Concentration (Cmin) PK analysis set included all available plasma concentrations and PK parameters for guadecitabine and decitabine for participants who received study drug. Overall number of participants analyzed are the number of participants available for analysis. Number analyzed are the number of participants with data available for analysis at the given timepoint.
Posted Geometric Mean Geometric Coefficient of Variation ng/mL Days 5 and 8 ID Title Description OG000 Dose Escalation: Regimen 1: Once Daily - 3 mg/m^2 Participants received starting dose of guadecitabine 3 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG001 Dose Escalation: Regimen 1: Once Daily - 9 mg/m^2 Participants received starting dose of guadecitabine 9 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG002 Dose Escalation: Regimen 1: Once Daily - 18 mg/m^2 Participants received starting dose of guadecitabine 18 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG003 Dose Escalation: Regimen 1: Once Daily - 36 mg/m^2
Secondary Dose Escalation: Area Under the Curve to Infinity (AUC0-inf) Pharmacokinetic (PK) analysis set included all available plasma concentrations and PK parameters for guadecitabine and decitabine for participants who received study drug. Overall number of participants analyzed are the number of participants available for analysis. Number analyzed are the number of participants with data available for analysis at the given timepoint.
Posted Geometric Mean Geometric Coefficient of Variation ng*hr/mL Days 1, 5 and 8 ID Title Description OG000 Dose Escalation: Regimen 1: Once Daily - 3 mg/m^2 Participants received starting dose of guadecitabine 3 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG001 Dose Escalation: Regimen 1: Once Daily - 9 mg/m^2 Participants received starting dose of guadecitabine 9 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG002 Dose Escalation: Regimen 1: Once Daily - 18 mg/m^2 Participants received starting dose of guadecitabine 18 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG003 Dose Escalation: Regimen 1: Once Daily - 36 mg/m^2
Secondary Dose Escalation and DE Phase- r/r MDS, TN MDS: Time to AML or Death Time to AML or death was defined as the number of days from the date the subject received the first dose of guadecitabine (C1D1) to the date of death or the date of MDS/ chronic myelomonocytic leukemia (CMML) progression to AML, whichever occurred earlier. Time to AML or death was evaluated using the Kaplan-Meier method, with the time censored on the last date of contact if a participant was still alive without progression to AML.
Efficacy analysis set included Regimen 1, 2A, 2B, r/r MDS and TN MDS participants who received at least one dose of study drug.
Posted Median Full Range days At end of each Cycle of 28 days (Up to approximately 38 months) ID Title Description OG000 Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Participants received starting dose of guadecitabine 3 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG001 Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Secondary Dose Escalation and DE Phases- r/r AML, TN AML, r/r MDS, TN MDS: Overall Survival OS was defined as the number of days from the day the participant received the first dose of guadecitabine to the date of death (regardless of cause).
Efficacy analysis set included participants who received at least one dose of study drug.
Posted Median Full Range days At end of each Cycle of 28 days (Up to approximately 45 months) ID Title Description OG000 Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Participants received starting dose of guadecitabine 3 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG001 Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG002 Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Secondary Dose Escalation: Number of Participants Achieving Blood and Platelet Transfusions Efficacy analysis set included all participants who received at least one dose of study drug. Overall number of participants are the number of participants with data available for analysis.
Posted Number percentage of participants Cycle 1, Day 1 through 30 days after the last dose of study drug (up to approximately 46 months) ID Title Description OG000 Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Participants received starting dose of guadecitabine 3 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG001 Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG002 Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Secondary DE Phase- r/r AML, TN AML: Percentage of Participants With Cr, CRp and PR CR is defined absolute neutrophil count (ANC) >1.0×109/L, Platelets ≥100×109/L, independence from RBC and platelet transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRp is defined ANC >1.0×10^9/L, Platelets <100×10^9/L, independence from RBC transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRi is defined as ANC <1.0×10^9/L, no myeloblasts and <5% myeloblasts in bone marrow. PR is defined as ANC >1.0×10^9/L, Platelets ≥100×10^9/L, no myeloblasts and Decrease of ≥50% in myeloblasts to level of 5% to 25% in bone marrow.
Efficacy analysis set included r/r AML and TN AML participants who received at least one dose of study drug.
Posted Number percentage of participants At end of each Cycle of 28 days (Up to approximately 45 months) ID Title Description OG000 Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily, from Days 1-5 of a 28-day cycle in participants with diagnosis of r/r AML.
OG001 Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5of a 28-day cycle in participants with a diagnosis of r/r AML.
OG002
Secondary DE Phase- r/r MDS, TN MDS: Percentage of Participants With CR, PR, mCR and HI CR is defined ANC >1.0×109/L, Platelets ≥100×109/L, independence from RBC and platelet transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRp is defined ANC >1.0×10^9/L, Platelets <100×10^9/L, independence from RBC transfusions over the past week, no myeloblasts and <5% myeloblasts in bone marrow. CRi is defined as ANC <1.0×10^9/L, no myeloblasts and <5% myeloblasts in bone marrow. PR is defined as ANC >1.0×10^9/L, Platelets ≥100×10^9/L, no myeloblasts and Decrease of ≥50% in myeloblasts to level of 5% to 25% in bone marrow.
Efficacy analysis set included r/r MDS and TN MDS participants who received at least one dose of study drug. Overall number of participants are the number of participants with data available for analysis.
Posted Number percentage of participants At end of each Cycle of 28 days (Up to approximately 45 months) ID Title Description OG000 Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of r/r MDS.
OG001 Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily on Days 1-5of a 28-day cycle in participants with a diagnosis of r/r MDS.
Secondary DE Phase- r/r MDS, TN MDS: Number of Participants Achieving Blood Transfusion Independence for 8 or 16-weeks Transfusion dependence at baseline was defined as any transfusion within 4 weeks of the first study dose (C1D1) with C1D1 transfusion counted, assuming it was always done before dosing. Transfusion independence after treatment was defined as no transfusion within an 8-week or 16-week period between C1D1 and last treatment date + 30 days.
Efficacy analysis set included r/r MDS and TN MDS participants who received at least one dose of study drug. Overall Number of Participants Analyzed are those who were dependent on RBC transfusions at baseline.
Posted Count of Participants Participants Weeks 8 and 16 ID Title Description OG000 Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of r/r MDS.
OG001 Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily on Days 1-5of a 28-day cycle in participants with a diagnosis of r/r MDS.
OG002 Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day)
Secondary DE Phase- r/r MDS, TN MDS: Number of Participants Achieving Platelet Transfusion Independence for 8 or 16-weeks Transfusion dependence at baseline was defined as any transfusion within 4 weeks of the first study dose (C1D1) with C1D1 transfusion counted, assuming it was always done before dosing. Transfusion independence after treatment was defined as no transfusion within an 8-week or 16-week period between C1D1 and last treatment date + 30 days.
Efficacy analysis set included r/r MDS and TN MDS participants who received at least one dose of study drug. Overall Number of Participants Analyzed are those who were dependent on platelet transfusions at baseline.
Posted Count of Participants Participants Weeks 8 and 16 ID Title Description OG000 Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of r/r MDS.
OG001 Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily on Days 1-5of a 28-day cycle in participants with a diagnosis of r/r MDS.
OG002 Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day)
From first dose of study drug up to 30 days post study treatment (up to 46 months)
All-cause mortality is reported for all enrolled participants. Serious adverse events are reported for safety set which included data from all participants who received at least one dose of study drug. Reconciling the >=5% adverse event data collected in multiple cohorts in trials conducted approximately 10 years ago cannot be provided as a single comprehensive data set, therefore no data is available to report for this safety section.
All-Cause Mortality Comment Not provided
ID Title Description Deaths (Affected) Deaths (At Risk) Serious Events (Affected) Serious Events (At Risk) Other Events (Affected) Other Events (At Risk) EG000 Dose Escalation: Regimen 1 - Guadecitabine 3 mg/m^2 Daily Participants received starting dose of guadecitabine 3 milligrams per meter square (mg/m^2), subcutaneously (SC), daily from Days 1-5 of a 28-day cycle. The dose was subsequently increased to 9, 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
5 44 33 44 44 44 EG001 Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15 of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
4 35 28 34 34 34 EG002 Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18 of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
0 15 8 15 15 15 EG003 Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily,from Days 1-5 of a 28-day cycle in participants with diagnosis of relapsed/refractory (r/r) AML.
4 25 19 24 24 24 EG004 Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5of a 28-day cycle in participants with a diagnosis of r/r AML.
3 28 21 26 26 26 EG005 Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5 and 8-12of a 28-day cycle in participants with a diagnosis of r/r AML.
10 55 44 53 53 53 EG006 Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, dailyfrom Days 1-5, SC of a 28-day cycle in participants with a diagnosis of treatment naïve (TN) AML.
4 24 21 24 24 24 EG007 Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5of a 28-day cycle in participants with a diagnosis of TN AML.
7 27 24 27 27 27 EG008 Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) Participants received guadecitabine 60 mg/m^2, SC, daily, from Days 1-5 and 8-12of a 28-day cycle in participants with a diagnosis of TN AML.
11 52 45 52 52 52 EG009 Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of r/r Myelodysplastic Syndromes (MDS).
2 26 17 26 26 26 EG010 Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily on Days 1-5of a 28-day cycle in participants with a diagnosis of r/r MDS.
4 27 22 27 27 27 EG011 Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
1 27 17 27 27 27 EG012 Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC. daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
2 22 17 22 22 22
Term Organ System Source Vocabulary Assessment Type Notes Statistical Information Anaemia Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 11 affected 44 at risk EG001 8 affected 34 at risk EG002 5 affected 15 at risk EG003 6 affected 24 at risk EG004 6 affected 26 at risk EG005 28 affected 53 at risk EG006 11 affected 24 at risk EG007 10 affected 27 at risk EG008 14 affected 52 at risk EG009 15 affected 26 at risk EG010 13 affected 27 at risk EG011 11 affected 27 at risk EG012 13 affected 22 at risk Coagulopathy Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Febrile neutropenia Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 5 affected 44 at risk EG001 5 affected 34 at risk EG002 3 affected 15 at risk EG003 Leukocytosis Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 4 affected 44 at risk EG001 6 affected 34 at risk EG002 1 affected 15 at risk EG003 Leukopenia Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 3 affected 44 at risk EG001 4 affected 34 at risk EG002 1 affected 15 at risk EG003 Lymph node pain Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Lymphadenopathy Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Lymphopenia Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Neutropenia Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 9 affected 44 at risk EG001 2 affected 34 at risk EG002 4 affected 15 at risk EG003 Splenomegaly Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Thrombocytopenia Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 14 affected 44 at risk EG001 6 affected 34 at risk EG002 4 affected 15 at risk EG003 Acute myocardial infarction Cardiac disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 2 affected 34 at risk EG002 0 affected 15 at risk EG003 Angina pectoris Cardiac disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Atrial fibrillation Cardiac disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 2 affected 34 at risk EG002 1 affected 15 at risk EG003 Atrial flutter Cardiac disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Atrial tachycardia Cardiac disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Atrial thrombosis Cardiac disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Bradycardia Cardiac disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Cardiac failure congestive Cardiac disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Cardiomyopathy Cardiac disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Palpitations Cardiac disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Pericardial effusion Cardiac disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Sinus tachycardia Cardiac disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Supraventricular tachycardia Cardiac disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Tachycardia Cardiac disorders 14.0 Systematic Assessment EG000 4 affected 44 at risk EG001 3 affected 34 at risk EG002 0 affected 15 at risk EG003 Auricular swelling Ear and labyrinth disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Cerumen impaction Ear and labyrinth disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Deafness Ear and labyrinth disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Deafness bilateral Ear and labyrinth disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Ear pain Ear and labyrinth disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hearing impaired Ear and labyrinth disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Conjunctival haemorrhage Eye disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Dry eye Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Eye haemorrhage Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Eye irritation Eye disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Vision blurred Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Abdominal discomfort Gastrointestinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Abdominal distension Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 3 affected 34 at risk EG002 0 affected 15 at risk EG003 Abdominal pain Gastrointestinal disorders 14.0 Systematic Assessment EG000 5 affected 44 at risk EG001 4 affected 34 at risk EG002 0 affected 15 at risk EG003 Abdominal pain upper Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Anal fissure Gastrointestinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Ascites Gastrointestinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Breath odour Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Constipation Gastrointestinal disorders 14.0 Systematic Assessment EG000 8 affected 44 at risk EG001 6 affected 34 at risk EG002 2 affected 15 at risk EG003 Diarrhoea Gastrointestinal disorders 14.0 Systematic Assessment EG000 22 affected 44 at risk EG001 11 affected 34 at risk EG002 2 affected 15 at risk EG003 Dry mouth Gastrointestinal disorders 14.0 Systematic Assessment EG000 3 affected 44 at risk EG001 3 affected 34 at risk EG002 0 affected 15 at risk EG003 Dyspepsia Gastrointestinal disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 2 affected 34 at risk EG002 1 affected 15 at risk EG003 Faecal incontinence Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Faeces discoloured Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Flatulence Gastrointestinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Gastrointestinal haemorrhage Gastrointestinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Gastrooesophageal reflux disease Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Gingival bleeding Gastrointestinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 1 affected 15 at risk EG003 Gingival erythema Gastrointestinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Gingival pain Gastrointestinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Gingival swelling Gastrointestinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Glossodynia Gastrointestinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Haematemesis Gastrointestinal disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Haematochezia Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 1 affected 15 at risk EG003 Haemorrhoids Gastrointestinal disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Lip blister Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Lip dry Gastrointestinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Melaena Gastrointestinal disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Mouth haemorrhage Gastrointestinal disorders 14.0 Systematic Assessment EG000 3 affected 44 at risk EG001 1 affected 34 at risk EG002 2 affected 15 at risk EG003 Nausea Gastrointestinal disorders 14.0 Systematic Assessment EG000 12 affected 44 at risk EG001 9 affected 34 at risk EG002 0 affected 15 at risk EG003 Oesophageal pain Gastrointestinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Oesophagitis Gastrointestinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Oral disorder Gastrointestinal disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Oral mucosal discolouration Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Oral pain Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 2 affected 15 at risk EG003 Proctalgia Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Rectal haemorrhage Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Rectal ulcer Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Stomatitis Gastrointestinal disorders 14.0 Systematic Assessment EG000 6 affected 44 at risk EG001 3 affected 34 at risk EG002 3 affected 15 at risk EG003 Stomatitis necrotising Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Swollen tongue Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Tongue ulceration Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Vomiting Gastrointestinal disorders 14.0 Systematic Assessment EG000 10 affected 44 at risk EG001 5 affected 34 at risk EG002 0 affected 15 at risk EG003 Asthenia General disorders 14.0 Systematic Assessment EG000 4 affected 44 at risk EG001 7 affected 34 at risk EG002 3 affected 15 at risk EG003 Catheter site erythema General disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Catheter site pain General disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Chest discomfort General disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Chest pain General disorders 14.0 Systematic Assessment EG000 3 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Chills General disorders 14.0 Systematic Assessment EG000 3 affected 44 at risk EG001 5 affected 34 at risk EG002 2 affected 15 at risk EG003 Device occlusion General disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Face oedema General disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Fatigue General disorders 14.0 Systematic Assessment EG000 11 affected 44 at risk EG001 9 affected 34 at risk EG002 7 affected 15 at risk EG003 Gait disturbance General disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Generalised oedema General disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Infusion site induration General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Injection site discomfort General disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Injection site haematoma General disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 2 affected 34 at risk EG002 0 affected 15 at risk EG003 Injection site haemorrhage General disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 2 affected 15 at risk EG003 Injection site mass General disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Injection site nodule General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Injection site pain General disorders 14.0 Systematic Assessment EG000 11 affected 44 at risk EG001 11 affected 34 at risk EG002 9 affected 15 at risk EG003 Injection site reaction General disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 1 affected 34 at risk EG002 2 affected 15 at risk EG003 Localised oedema General disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Non-cardiac chest pain General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Oedema General disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Oedema peripheral General disorders 14.0 Systematic Assessment EG000 11 affected 44 at risk EG001 9 affected 34 at risk EG002 3 affected 15 at risk EG003 Pain General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Pyrexia General disorders 14.0 Systematic Assessment EG000 7 affected 44 at risk EG001 8 affected 34 at risk EG002 1 affected 15 at risk EG003 Systemic inflammatory response syndrome General disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Cholecystitis Hepatobiliary disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hepatomegaly Hepatobiliary disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hyperbilirubinaemia Hepatobiliary disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 1 affected 15 at risk EG003 Jaundice Hepatobiliary disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Drug hypersensitivity Immune system disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hypersensitivity Immune system disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hypogammaglobulinaemia Immune system disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Immune system disorder Immune system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Seasonal allergy Immune system disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Abscess jaw Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Acute haemorrhagic conjunctivitis Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Acute sinusitis Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Bacteraemia Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Candidiasis Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Cellulitis Infections and infestations 14.0 Systematic Assessment EG000 7 affected 44 at risk EG001 4 affected 34 at risk EG002 0 affected 15 at risk EG003 Clostridium difficile colitis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 2 affected 15 at risk EG003 Cystitis Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Device related infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Ear infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Enterococcal bacteraemia Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Folliculitis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Fungal skin infection Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Herpes simplex Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 2 affected 34 at risk EG002 0 affected 15 at risk EG003 Herpes virus infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Infection Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Influenza Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Lip infection Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Mastoiditis Immune system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Nasopharyngitis Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Oral candidiasis Infections and infestations 14.0 Systematic Assessment EG000 3 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Oral fungal infection Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Oral herpes Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Otitis media Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Parotitis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 2 affected 34 at risk EG002 0 affected 15 at risk EG003 Pneumonia Infections and infestations 14.0 Systematic Assessment EG000 8 affected 44 at risk EG001 4 affected 34 at risk EG002 1 affected 15 at risk EG003 Rhinitis Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Sialoadenitis Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Sinusitis Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Soft tissue infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Staphylococcal infection Infections and infestations 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Streptococcal urinary tract infection Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Tooth abscess Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Tooth infection Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Upper respiratory tract infection Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 5 affected 34 at risk EG002 1 affected 15 at risk EG003 Urethritis Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Urinary tract infection Infections and infestations 14.0 Systematic Assessment EG000 5 affected 44 at risk EG001 5 affected 34 at risk EG002 1 affected 15 at risk EG003 Urinary tract infection enterococcal Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Vaginal infection Infections and infestations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Wound infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 2 affected 34 at risk EG002 0 affected 15 at risk EG003 Allergic transfusion reaction Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Burns first degree Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Contusion Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 6 affected 44 at risk EG001 4 affected 34 at risk EG002 3 affected 15 at risk EG003 Excoriation Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 3 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Fall Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 1 affected 34 at risk EG002 1 affected 15 at risk EG003 Infusion related reaction Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Joint sprain Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Open wound Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Periorbital haematoma Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Procedural pain Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Skin injury Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Underdose Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Wound haemorrhage Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Activated partial thromboplastin time Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Alanine aminotransferase increased Investigations 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Aspartate aminotransferase increased Investigations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Blood alkaline phosphatase decreased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Blood alkaline phosphatase increased Investigations 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Blood bilirubin increased Investigations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 2 affected 34 at risk EG002 0 affected 15 at risk EG003 Blood creatinine decreased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Blood creatinine increased Investigations 14.0 Systematic Assessment EG000 3 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Blood fibrinogen increased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Blood lactate dehydrogenase increased Investigations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Blood magnesium increased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Blood potassium increased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Blood urine present Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Breath sounds abnormal Investigations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Cardiac murmur Investigations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Electrocardiogram qt prolonged Investigations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Fibrinolysis increased Investigations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hepatic enzyme increased Investigations 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 International normalised ratio increased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 3 affected 34 at risk EG002 0 affected 15 at risk EG003 Occult blood positive Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Transaminases increased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Weight decreased Investigations 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 3 affected 34 at risk EG002 1 affected 15 at risk EG003 White blood cell count increased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Decreased appetite Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 9 affected 44 at risk EG001 4 affected 34 at risk EG002 4 affected 15 at risk EG003 Dehydration Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 4 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Failure to thrive Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Fluid retention Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Hypercalcaemia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Hyperchloraemia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hyperglycaemia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 6 affected 44 at risk EG001 5 affected 34 at risk EG002 0 affected 15 at risk EG003 Hyperkalaemia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Hypermagnesaemia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Hypernatraemia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Hyperphosphataemia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hyperuricaemia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hypoalbuminaemia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 6 affected 44 at risk EG001 3 affected 34 at risk EG002 0 affected 15 at risk EG003 Hypocalcaemia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 4 affected 44 at risk EG001 3 affected 34 at risk EG002 0 affected 15 at risk EG003 Hypokalaemia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 5 affected 44 at risk EG001 9 affected 34 at risk EG002 1 affected 15 at risk EG003 Hypomagnesaemia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 5 affected 44 at risk EG001 6 affected 34 at risk EG002 2 affected 15 at risk EG003 Hyponatraemia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 6 affected 34 at risk EG002 1 affected 15 at risk EG003 Hypophosphataemia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 5 affected 44 at risk EG001 4 affected 34 at risk EG002 0 affected 15 at risk EG003 Hypouricaemia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Lactic acidosis Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Metabolic acidosis Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 3 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Metabolic alkalosis Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Polydipsia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Tumour lysis syndrome Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Arthralgia Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 5 affected 44 at risk EG001 6 affected 34 at risk EG002 0 affected 15 at risk EG003 Arthritis Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Back pain Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 4 affected 44 at risk EG001 4 affected 34 at risk EG002 1 affected 15 at risk EG003 Bone pain Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 3 affected 34 at risk EG002 0 affected 15 at risk EG003 Flank pain Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 1 affected 15 at risk EG003 Groin pain Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 3 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Joint stiffness Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Joint swelling Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Limb discomfort Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Muscle spasms Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Muscular weakness Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Musculoskeletal chest pain Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Musculoskeletal pain Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 3 affected 44 at risk EG001 3 affected 34 at risk EG002 2 affected 15 at risk EG003 Musculoskeletal stiffness Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Myalgia Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 5 affected 44 at risk EG001 4 affected 34 at risk EG002 1 affected 15 at risk EG003 Neck pain Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 2 affected 34 at risk EG002 0 affected 15 at risk EG003 Pain in extremity Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 5 affected 44 at risk EG001 3 affected 34 at risk EG002 2 affected 15 at risk EG003 Trigger finger Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Acanthoma Neoplasms benign, malignant and unspecified (incl cysts and polyps) 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Seborrhoeic keratosis Neoplasms benign, malignant and unspecified (incl cysts and polyps) 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Squamous cell carcinoma Neoplasms benign, malignant and unspecified (incl cysts and polyps) 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Aphasia Nervous system disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Consciousness fluctuating Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Dementia Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Dizziness Nervous system disorders 14.0 Systematic Assessment EG000 5 affected 44 at risk EG001 3 affected 34 at risk EG002 2 affected 15 at risk EG003 Dysgeusia Nervous system disorders 14.0 Systematic Assessment EG000 4 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Haemorrhage intracranial Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Headache Nervous system disorders 14.0 Systematic Assessment EG000 9 affected 44 at risk EG001 6 affected 34 at risk EG002 3 affected 15 at risk EG003 Hypoaesthesia Nervous system disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Lethargy Nervous system disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Pachymeningitis Nervous system disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Peripheral sensory neuropathy Nervous system disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Peroneal nerve palsy Nervous system disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Presyncope Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Sinus headache Nervous system disorders 14.0 Systematic Assessment EG000 3 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Somnolence Nervous system disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Syncope Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 1 affected 15 at risk EG003 Tremor Nervous system disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Viith nerve paralysis Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Agitation Psychiatric disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Anxiety Psychiatric disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 3 affected 34 at risk EG002 1 affected 15 at risk EG003 Depression Psychiatric disorders 14.0 Systematic Assessment EG000 5 affected 44 at risk EG001 1 affected 34 at risk EG002 1 affected 15 at risk EG003 Hallucination, visual Psychiatric disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Insomnia Psychiatric disorders 14.0 Systematic Assessment EG000 5 affected 44 at risk EG001 8 affected 34 at risk EG002 0 affected 15 at risk EG003 Mental status changes Psychiatric disorders 14.0 Systematic Assessment EG000 3 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Psychotic disorder Psychiatric disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Restlessness Psychiatric disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Dysuria Renal and urinary disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Haematuria Renal and urinary disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 3 affected 34 at risk EG002 2 affected 15 at risk EG003 Micturition urgency Renal and urinary disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 1 affected 15 at risk EG003 Nocturia Renal and urinary disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 1 affected 15 at risk EG003 Oliguria Renal and urinary disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Pollakiuria Renal and urinary disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 1 affected 34 at risk EG002 1 affected 15 at risk EG003 Polyuria Renal and urinary disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Renal failure Renal and urinary disorders 14.0 Systematic Assessment EG000 5 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Renal failure acute Renal and urinary disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 1 affected 15 at risk EG003 Renal impairment Renal and urinary disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Urinary incontinence Renal and urinary disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 2 affected 34 at risk EG002 1 affected 15 at risk EG003 Urinary retention Renal and urinary disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Urinary tract pain Renal and urinary disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 1 affected 15 at risk EG003 Breast mass Reproductive system and breast disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Prostatic obstruction Reproductive system and breast disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Vulvovaginal dryness Reproductive system and breast disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Bronchostenosis Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Chronic obstructive pulmonary disease Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Cough Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 12 affected 44 at risk EG001 9 affected 34 at risk EG002 2 affected 15 at risk EG003 Dyspnoea Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 11 affected 44 at risk EG001 11 affected 34 at risk EG002 3 affected 15 at risk EG003 Epistaxis Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 11 affected 44 at risk EG001 4 affected 34 at risk EG002 3 affected 15 at risk EG003 Haemoptysis Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 3 affected 34 at risk EG002 1 affected 15 at risk EG003 Hypoxia Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 2 affected 34 at risk EG002 0 affected 15 at risk EG003 Lung disorder Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Nasal congestion Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 8 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Oropharyngeal blistering Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Oropharyngeal pain Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 4 affected 44 at risk EG001 0 affected 34 at risk EG002 2 affected 15 at risk EG003 Paranasal sinus mucosal hypertrophy Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Pleural effusion Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 3 affected 44 at risk EG001 2 affected 34 at risk EG002 1 affected 15 at risk EG003 Pleuritic pain Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Rales Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 2 affected 34 at risk EG002 0 affected 15 at risk EG003 Respiratory failure Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Rhinitis allergic Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Rhinorrhoea Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Rhonchi Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Sinus congestion Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Tachypnoea Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Upper-airway cough syndrome Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Vocal cord cyst Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Wheezing Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 2 affected 34 at risk EG002 0 affected 15 at risk EG003 Acute febrile neutrophilic dermatosis Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 2 affected 34 at risk EG002 0 affected 15 at risk EG003 Alopecia Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 1 affected 34 at risk EG002 1 affected 15 at risk EG003 Blister Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Blood blister Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Decubitus ulcer Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Dermatitis Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Dermatitis allergic Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Diabetic ulcer Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Dry skin Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 3 affected 44 at risk EG001 2 affected 34 at risk EG002 0 affected 15 at risk EG003 Ecchymosis Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 2 affected 34 at risk EG002 2 affected 15 at risk EG003 Erythema Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 4 affected 44 at risk EG001 6 affected 34 at risk EG002 1 affected 15 at risk EG003 Hyperhidrosis Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Ingrowing nail Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Night sweats Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 2 affected 34 at risk EG002 0 affected 15 at risk EG003 Petechiae Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 6 affected 44 at risk EG001 1 affected 34 at risk EG002 3 affected 15 at risk EG003 Pruritus Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 2 affected 34 at risk EG002 2 affected 15 at risk EG003 Pruritus generalised Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Purpura Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Rash Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 7 affected 44 at risk EG001 9 affected 34 at risk EG002 3 affected 15 at risk EG003 Rash maculo-papular Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Skin exfoliation Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Skin irritation Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 1 affected 15 at risk EG003 Skin lesion Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 2 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Skin ulcer Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 2 affected 34 at risk EG002 1 affected 15 at risk EG003 Urticaria Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 2 affected 34 at risk EG002 2 affected 15 at risk EG003 Sinus operation Surgical and medical procedures 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Skin neoplasm excision Surgical and medical procedures 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 1 affected 34 at risk EG002 0 affected 15 at risk EG003 Vagotomy Surgical and medical procedures 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Capillary leak syndrome Vascular disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Haematoma Vascular disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 2 affected 34 at risk EG002 2 affected 15 at risk EG003 Hypertension Vascular disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 3 affected 34 at risk EG002 2 affected 15 at risk EG003 Hypotension Vascular disorders 14.0 Systematic Assessment EG000 10 affected 44 at risk EG001 4 affected 34 at risk EG002 2 affected 15 at risk EG003 Pallor Vascular disorders 14.0 Systematic Assessment EG000 1 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Disseminated intravascular coagulation Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Febrile neutropenia Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hypoprothrombinaemia Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Lymphadenitis Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Lymphadenopathy Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Thrombocytosis Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Arrhythmia Cardiac disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Atrioventricular block Cardiac disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Cardiac failure Cardiac disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Cardiomyopathy Cardiac disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Left ventricular dysfunction Cardiac disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Sinus arrhythmia Cardiac disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Palpitations Cardiac disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Pericardial effusion Cardiac disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Ventricular fibrillation Cardiac disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Ear discomfort Ear and labyrinth disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Ear disorder Ear and labyrinth disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Ear pain Ear and labyrinth disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 External ear disorder Ear and labyrinth disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Vertigo Ear and labyrinth disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Vertigo positional Ear and labyrinth disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Abnormal sensation in eye Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Cataract Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Conjunctival haemorrhage Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Conjunctivitis Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Dry eye Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Eye pain Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Eye swelling Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Keratopathy Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Ocular discomfort Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Ocular hyperaemia Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Photophobia Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Retinal haemorrhage Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Scleral disorder Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Scleral haemorrhage Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Scotoma Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Visual impairment Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Vitreous floaters Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Abdominal mass Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Abdominal pain lower Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Caecitis Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Colitis Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Dental caries Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Dysphagia Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Gingival hyperplasia Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Gingival hypertrophy Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Gingival ulceration Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Haemorrhoidal haemorrhage Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Ileus Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Lip pain Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Lip swelling Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Lip ulceration Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Mouth ulceration Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Rectal fissure Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Tongue disorder Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Toothache Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Umbilical hernia Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Axillary pain General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Catheter site related reaction General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Cyst General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Exercise tolerance decreased General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Feeling cold General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Injection site erythema General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Injection site inflammation General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Injection site swelling General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Malaise General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Mucosal dryness General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Nodule General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Swelling General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Cholelithiasis Hepatobiliary disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hepatic lesion Hepatobiliary disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Graft versus host disease Immune system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Abdominal abscess Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Abdominal infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Abscess Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Appendicitis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Bacterial infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Bk virus infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Cytomegalovirus infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Diverticulitis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Epiglottitis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Epstein-barr viraemia Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Escherichia urinary tract infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Fusarium infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Gingival infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Helicobacter gastritis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Herpes zoster Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Impetigo Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Injection site infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Klebsiella infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Mycobacterium kansasii infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Parainfluenzae virus infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Paronychia Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Pericoronitis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Puncture site infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Respiratory tract infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Rhinovirus infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Sepsis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Streptococcal bacteraemia Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Sweating fever Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Tonsillitis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Tracheostomy infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Urosepsis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Incision site pain Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Laceration Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Lip injury Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Post procedural haemorrhage Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Transfusion reaction Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Wound Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Blood amylase increased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Blood creatine increased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Blood glucose increased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Blood urea increased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Glomerular filtration rate decreased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Lipase increased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Red blood cell count decreased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Sputum culture Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Troponin i increased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Acidosis Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Electrolyte imbalance Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Fluid overload Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Glucose tolerance impaired Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hypertriglyceridaemia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hypervolaemia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hypoglycaemia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hypovolaemia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Iron overload Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Bursitis Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Osteoporosis Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Pain in jaw Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Rheumatoid nodule Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Soft tissue disorder Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Tendon pain Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Epstein-barr virus associated lymphoproliferative disorder Neoplasms benign, malignant and unspecified (incl cysts and polyps) 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Lipoma Neoplasms benign, malignant and unspecified (incl cysts and polyps) 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Metastases to meninges Neoplasms benign, malignant and unspecified (incl cysts and polyps) 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Uterine leiomyoma Neoplasms benign, malignant and unspecified (incl cysts and polyps) 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Burning sensation Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Carotid artery stenosis Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Carpal tunnel syndrome Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Dysarthria Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Dyskinesia Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hypersomnia Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Nervous system disorder Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Neuralgia Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Neuropathy peripheral Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Paraesthesia Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Restless legs syndrome Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Transient ischaemic attack Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Vocal cord paralysis Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Delirium Psychiatric disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Disorientation Psychiatric disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hallucination Psychiatric disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Mental disorder Psychiatric disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Chromaturia Renal and urinary disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Proteinuria Renal and urinary disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Pelvic pain Reproductive system and breast disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Scrotal oedema Reproductive system and breast disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Vaginal fistula Reproductive system and breast disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Vaginal haemorrhage Reproductive system and breast disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Vulvar erosion Reproductive system and breast disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Atelectasis Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Dysphonia Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Dyspnoea exertional Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hiccups Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Laryngeal inflammation Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Lung infiltration Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Nasal discomfort Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Obliterative bronchiolitis Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Pneumothorax Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Productive cough Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Pulmonary alveolar haemorrhage Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Pulmonary oedema Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Respiratory distress Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Drug eruption Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Facial wasting Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Lipohypertrophy Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Skin discolouration Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Skin hyperpigmentation Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Skin induration Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Enterostomy Surgical and medical procedures 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Maxillofacial operation Surgical and medical procedures 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Deep vein thrombosis Vascular disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Haemorrhage Vascular disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Orthostatic hypotension Vascular disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Thrombophlebitis Vascular disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Thrombophlebitis superficial Vascular disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Bone marrow failure Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Lymphatic disorder Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Pancytopenia Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Thrombotic thrombocytopenic purpura Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Ventricular tachycardia Cardiac disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Arteriovenous malformation Congenital, familial and genetic disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Eustachian tube dysfunction Ear and labyrinth disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Adrenal insufficiency Endocrine disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Goitre Endocrine disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hypothyroidism Endocrine disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Blepharitis Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Conjunctival pallor Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Corneal erosion Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Eye pruritus Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Eyelid disorder Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Keratitis Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Periorbital oedema Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Pupillary disorder Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Scleral pigmentation Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Cheilitis Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Dental discomfort Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Diverticulum Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Duodenal ulcer haemorrhage Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Epigastric discomfort Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Eructation Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Gastritis Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Gastrointestinal pain Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Gingival hypertrophy Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hypoaesthesia oral Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Loose tooth Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Oesophageal ulcer Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Paraesthesia oral Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Periodontal disease Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Regurgitation Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Salivary hypersecretion Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Tooth disorder Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Adverse drug reaction General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Catheter site haemorrhage General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Infusion site reaction General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Injection site joint redness General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Mass General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Ulcer General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Vessel puncture site pain General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Sarcoidosis Immune system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Chronic sinusitis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Corona virus infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Diarrhoea infectious Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Gastroenteritis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Genital abscess Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Mycobacterium avium complex infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Oral infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Periorbital cellulitis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Pharyngeal abscess Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Pneumonia bacterial Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Rectal abscess Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Viral infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Viral pharyngitis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Arthropod bite Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Facial bones fracture Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Jaw fracture Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Limb injury Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Penis injury Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Rib fracture Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Subdural haematoma Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Sunburn Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Tendon rupture Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Thermal burn Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Aspergillus test positive Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Blood phosphorus decreased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Blood uric acid increased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Enterobacter test positive Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Gamma-glutamyltransferase increased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Haemoglobin decreased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Liver function test abnormal Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Platelet count decreased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Weight increased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Alkalosis hypochloraemic Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Cachexia Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Diabetes mellitus Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Gout Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Vitamin d deficiency Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Mobility decreased Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Muscle atrophy Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Rotator cuff syndrome Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Synovial cyst Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Temporomandibular joint syndrome Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Lip neoplasm malignant stage unspecified Neoplasms benign, malignant and unspecified (incl cysts and polyps) 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Amnesia Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Balance disorder Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Diabetic neuropathy Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Disturbance in attention Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Muscle contractions involuntary Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Neurological decompensation Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Sciatica Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Sedation Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Confusional state Psychiatric disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Delirium febrile Psychiatric disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Bladder pain Renal and urinary disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Bladder spasm Renal and urinary disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Nephrolithiasis Renal and urinary disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Renal failure chronic Renal and urinary disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Urinary hesitation Renal and urinary disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Urine odour abnormal Renal and urinary disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Breast discomfort Reproductive system and breast disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Testicular pain Reproductive system and breast disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Vaginal discharge Reproductive system and breast disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Acute respiratory failure Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Bronchospasm Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Chronic obstructive pulmonary disease Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Dry throat Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Increased upper airway secretion Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Nasal dryness Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Pharyngeal disorder Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Sleep apnoea syndrome Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Throat irritation Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Acne Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Actinic keratosis Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Butterfly rash Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Cold sweat Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Erythema multiforme Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hypoaesthesia facial Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Onychoclasis Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Onychomadesis Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Palmar-plantar erythrodysaesthesia syndrome Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Rash erythematous Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Rash morbilliform Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Seborrhoea Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Seborrhoeic dermatitis Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Swelling face Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Nail operation Surgical and medical procedures 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Tooth extraction Surgical and medical procedures 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hypoperfusion Vascular disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Phlebitis Vascular disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Thrombosis Vascular disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Splenic infarction Blood and lymphatic system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hydrocele Congenital, familial and genetic disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Phimosis Congenital, familial and genetic disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Ear congestion Ear and labyrinth disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Ear haemorrhage Ear and labyrinth disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hypoacusis Ear and labyrinth disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Middle ear effusion Ear and labyrinth disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Tinnitus Ear and labyrinth disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Autoimmune thyroiditis Endocrine disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Inappropriate antidiuretic hormone secretion Endocrine disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Chalazion Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Conjunctival discolouration Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Conjunctival irritation Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Conjunctivitis allergic Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Lacrimation increased Eye disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Abdominal wall haematoma Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Anal ulcer Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Aphthous stomatitis Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Neutropenic colitis Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Odynophagia Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Oral mucosal erythema Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Tongue coated Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Tongue discolouration Gastrointestinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Crepitations General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hernia General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Induration General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Inflammation General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Influenza like illness General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Infusion site pain General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Injection site joint swelling General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Injection site pruritus General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Injection site rash General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Secretion discharge General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Tenderness General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Thirst General disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hepatic failure Hepatobiliary disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Portal hypertension Hepatobiliary disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Cellulitis of male external genital organ Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Coccidioidomycosis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Furuncle Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Haemophilus infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hepatitis c Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hordeolum Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Infected sebaceous cyst Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Injection site cellulitis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Labyrinthitis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Nail infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Nasal abscess Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Orchitis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Otitis media chronic Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Periorbital infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Perirectal abscess Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Pharyngitis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Pseudomonas infection Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Subcutaneous abscess Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Tuberculosis Infections and infestations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Animal scratch Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Ankle fracture Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Conjunctival scar Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Scratch Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Suture related complication Injury, poisoning and procedural complications 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Bacterial test positive Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Blood glucose abnormal Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Blood potassium decreased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Blood sodium decreased Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Electrocardiogram abnormal Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Enterococcus test positive Investigations 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Haemosiderosis Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Weight fluctuation Metabolism and nutrition disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Arthropathy Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Floating patella Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Joint contracture Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Tendonitis Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Musculoskeletal discomfort Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Osteoarthritis Musculoskeletal and connective tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Adrenal adenoma Neoplasms benign, malignant and unspecified (incl cysts and polyps) 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Leukaemia cutis Neoplasms benign, malignant and unspecified (incl cysts and polyps) 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Lung neoplasm Neoplasms benign, malignant and unspecified (incl cysts and polyps) 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Prostate cancer Neoplasms benign, malignant and unspecified (incl cysts and polyps) 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Cognitive disorder Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Dizziness postural Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Memory impairment Nervous system disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Anhedonia Psychiatric disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Sleep disorder Psychiatric disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Balanitis Reproductive system and breast disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Benign prostatic hyperplasia Reproductive system and breast disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Nasal polyps Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Orthopnoea Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Sinus disorder Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Sneezing Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Sputum increased Respiratory, thoracic and mediastinal disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Circumoral oedema Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Cutis laxa Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Dermatosis Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Rash generalised Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Rash macular Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Granuloma annulare Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Increased tendency to bruise Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Palpable purpura Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Perivascular dermatitis Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Skin mass Skin and subcutaneous tissue disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Cataract operation Surgical and medical procedures 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Embolism Vascular disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Flushing Vascular disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003 Hot flush Vascular disorders 14.0 Systematic Assessment EG000 0 affected 44 at risk EG001 0 affected 34 at risk EG002 0 affected 15 at risk EG003
Are all PI(s) employees of the sponsor? No
Results Disclosure Restriction on PI(s)? No
Title Organization Phone Extension Email Dr. Harold Keer Astex Pharmaceuticals, Inc. 925-560-2913 harold.keer@astx.com
ID Term C580831 guadecitabine
0 subjects
FG005 0 subjects
FG006 0 subjects
FG007 0 subjects
FG008 0 subjects
FG009 0 subjects
FG010 0 subjects
FG011 0 subjects
FG012 0 subjects 0 subjects
FG005 0 subjects
FG006 0 subjects
FG007 0 subjects
FG008 0 subjects
FG009 0 subjects
FG010 0 subjects
FG011 0 subjects
FG012 0 subjects 0 subjects
FG005 0 subjects
FG006 0 subjects
FG007 0 subjects
FG008 0 subjects
FG009 0 subjects
FG010 0 subjects
FG011 0 subjects
FG012 0 subjects 0 subjects
FG005 0 subjects
FG006 0 subjects
FG007 0 subjects
FG008 0 subjects
FG009 0 subjects
FG010 0 subjects
FG011 0 subjects
FG012 0 subjects 0 subjects
FG005 0 subjects
FG006 0 subjects
FG007 0 subjects
FG008 0 subjects
FG009 0 subjects
FG010 0 subjects
FG011 0 subjects
FG012 0 subjects 0 subjects
FG005 0 subjects
FG006 0 subjects
FG007 0 subjects
FG008 0 subjects
FG009 0 subjects
FG010 0 subjects
FG011 0 subjects
FG012 0 subjects 24 subjects
FG004 26 subjects
FG005 50 subjects
FG006 0 subjects
FG007 0 subjects
FG008 0 subjects
FG009 0 subjects
FG010 0 subjects
FG011 0 subjects
FG012 0 subjects 1 subjects
FG005 0 subjects
FG006 0 subjects
FG007 0 subjects
FG008 0 subjects
FG009 0 subjects
FG010 0 subjects
FG011 0 subjects
FG012 0 subjects 27 subjects
FG005 55 subjects
FG006 0 subjects
FG007 0 subjects
FG008 0 subjects
FG009 0 subjects
FG010 0 subjects
FG011 0 subjects
FG012 0 subjects 14 subjects
FG004 16 subjects
FG005 24 subjects
FG006 0 subjects
FG007 0 subjects
FG008 0 subjects
FG009 0 subjects
FG010 0 subjects
FG011 0 subjects
FG012 0 subjects Adverse Event FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004 2 subjects FG005 2 subjects FG006 0 subjects FG007 0 subjects FG008 0 subjects FG009 0 subjects FG010 0 subjects FG011 0 subjects FG012 0 subjects
Withdrew Consent FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004 1 subjects FG005 2 subjects FG006 0 subjects FG007 0 subjects FG008 0 subjects FG009 0 subjects FG010 0 subjects FG011 0 subjects FG012 0 subjects
Death FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 4 subjects FG004 3 subjects FG005 10 subjects FG006 0 subjects FG007 0 subjects FG008 0 subjects FG009 0 subjects FG010 0 subjects FG011 0 subjects FG012 0 subjects
Investigator Decision FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004 0 subjects FG005 6 subjects FG006 0 subjects FG007 0 subjects FG008 0 subjects FG009 0 subjects FG010 0 subjects FG011 0 subjects FG012 0 subjects
HCT FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 5 subjects FG004 3 subjects FG005 9 subjects FG006 0 subjects FG007 0 subjects FG008 0 subjects FG009 0 subjects FG010 0 subjects FG011 0 subjects FG012 0 subjects
Reason not Specified FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 1 subjects FG004 2 subjects FG005 2 subjects FG006 0 subjects FG007 0 subjects FG008 0 subjects FG009 0 subjects FG010 0 subjects FG011 0 subjects FG012 0 subjects
0 subjects
FG004 0 subjects
FG005 0 subjects
FG006 24 subjects
FG007 27 subjects
FG008 52 subjects
FG009 0 subjects
FG010 0 subjects
FG011 0 subjects
FG012 0 subjects 0 subjects
FG005 0 subjects
FG006 1 subjects
FG007 2 subjects
FG008 3 subjects
FG009 0 subjects
FG010 0 subjects
FG011 0 subjects
FG012 0 subjects 0 subjects
FG005 0 subjects
FG006 25 subjects
FG007 26 subjects
FG008 50 subjects
FG009 0 subjects
FG010 0 subjects
FG011 0 subjects
FG012 0 subjects 0 subjects
FG004 0 subjects
FG005 0 subjects
FG006 9 subjects
FG007 11 subjects
FG008 17 subjects
FG009 0 subjects
FG010 0 subjects
FG011 0 subjects
FG012 0 subjects Adverse Event FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004 0 subjects FG005 0 subjects FG006 0 subjects FG007 1 subjects FG008 2 subjects FG009 0 subjects FG010 0 subjects FG011 0 subjects FG012 0 subjects
Withdrew Consent FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004 0 subjects FG005 0 subjects FG006 3 subjects FG007 3 subjects FG008 3 subjects FG009 0 subjects FG010 0 subjects FG011 0 subjects FG012 0 subjects
Death FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004 0 subjects FG005 0 subjects FG006 4 subjects FG007 7 subjects FG008 11 subjects FG009 0 subjects FG010 0 subjects FG011 0 subjects FG012 0 subjects
Investigator Decision FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004 0 subjects FG005 0 subjects FG006 2 subjects FG007 2 subjects FG008 9 subjects FG009 0 subjects FG010 0 subjects FG011 0 subjects FG012 0 subjects
Bone marrow (BM)/Stem cell transplant FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004 0 subjects FG005 0 subjects FG006 2 subjects FG007 1 subjects FG008 2 subjects FG009 0 subjects FG010 0 subjects FG011 0 subjects FG012 0 subjects
Reason not Specified FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004 0 subjects FG005 0 subjects FG006 5 subjects FG007 1 subjects FG008 6 subjects FG009 0 subjects FG010 0 subjects FG011 0 subjects FG012 0 subjects
0 subjects
FG004 0 subjects
FG005 0 subjects
FG006 0 subjects
FG007 0 subjects
FG008 0 subjects
FG009 26 subjects
FG010 27 subjects
FG011 27 subjects
FG012 22 subjects 0 subjects
FG005 0 subjects
FG006 0 subjects
FG007 0 subjects
FG008 0 subjects
FG009 2 subjects
FG010 2 subjects
FG011 1 subjects
FG012 3 subjects 0 subjects
FG005 0 subjects
FG006 0 subjects
FG007 0 subjects
FG008 0 subjects
FG009 25 subjects
FG010 25 subjects
FG011 27 subjects
FG012 20 subjects 0 subjects
FG004 0 subjects
FG005 0 subjects
FG006 0 subjects
FG007 0 subjects
FG008 0 subjects
FG009 7 subjects
FG010 7 subjects
FG011 9 subjects
FG012 2 subjects Adverse Event FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004 0 subjects FG005 0 subjects FG006 0 subjects FG007 0 subjects FG008 0 subjects FG009 2 subjects FG010 0 subjects FG011 3 subjects FG012 3 subjects
Withdrew Consent FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004 0 subjects FG005 0 subjects FG006 0 subjects FG007 0 subjects FG008 0 subjects FG009 4 subjects FG010 5 subjects FG011 3 subjects FG012 3 subjects
Death FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004 0 subjects FG005 0 subjects FG006 0 subjects FG007 0 subjects FG008 0 subjects FG009 2 subjects FG010 4 subjects FG011 1 subjects FG012 2 subjects
Investigator Decision FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004 0 subjects FG005 0 subjects FG006 0 subjects FG007 0 subjects FG008 0 subjects FG009 5 subjects FG010 6 subjects FG011 3 subjects FG012 5 subjects
BM/Stem Cell Transplant FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004 0 subjects FG005 0 subjects FG006 0 subjects FG007 0 subjects FG008 0 subjects FG009 3 subjects FG010 1 subjects FG011 6 subjects FG012 4 subjects
Reason not Specified FG000 0 subjects FG001 0 subjects FG002 0 subjects FG003 0 subjects FG004 0 subjects FG005 0 subjects FG006 0 subjects FG007 0 subjects FG008 0 subjects FG009 2 subjects FG010 2 subjects FG011 2 subjects FG012 1 subjects
55.83
(22.0 to 77.0)
BG004 62.01 (30.0 to 81.7)
BG005 58.86 (29.2 to 82.5)
BG006 77.83 (62.0 to 92.5)
BG007 78.46 (66.7 to 92.6)
BG008 77.78 (66.4 to 92.3)
BG009 71.61 (54.7 to 85.5)
BG010 72.05 (51.9 to 88.7)
BG011 68.38 (18.1 to 85.3)
BG012 71.27 (63.8 to 84.5)
BG013 68.94 (18.1 to 92.6) 3
BG003 9
BG004 6
BG005 26
BG006 10
BG007 11
BG008 18
BG009 10
BG010 11
BG011 6
BG012 8
BG013 145 Male BG000 25 BG001 26 BG002 12 BG003 15 BG004 20 BG005 27 BG006 14 BG007 16 BG008 34 BG009 16 BG010 16 BG011 21 BG012 14 BG013 256
3
BG003 5
BG004 3
BG005 5
BG006 2
BG007 0
BG008 1
BG009 0
BG010 2
BG011 3
BG012 1
BG013 29 Not Hispanic or Latino BG000 42 BG001 32 BG002 12 BG003 19 BG004 23 BG005 48 BG006 22 BG007 27 BG008 51 BG009 26 BG010 25 BG011 24 BG012 21 BG013 372
Unknown or Not Reported BG000 0 BG001 0 BG002 0 BG003 0 BG004 0 BG005 0 BG006 0 BG007 0 BG008 0 BG009 0 BG010 0 BG011 0 BG012 0 BG013 0
0
BG003 0
BG004 0
BG005 0
BG006 0
BG007 0
BG008 0
BG009 0
BG010 0
BG011 0
BG012 0
BG013 0 Asian BG000 3 BG001 0 BG002 0 BG003 2 BG004 4 BG005 2 BG006 1 BG007 2 BG008 1 BG009 1 BG010 1 BG011 1 BG012 0 BG013 18
Native Hawaiian or Other Pacific Islander BG000 0 BG001 0 BG002 0 BG003 0 BG004 0 BG005 1 BG006 0 BG007 0 BG008 1 BG009 0 BG010 0 BG011 0 BG012 0 BG013 2
Black or African American BG000 2 BG001 3 BG002 1 BG003 4 BG004 0 BG005 5 BG006 0 BG007 0 BG008 0 BG009 0 BG010 1 BG011 0 BG012 0 BG013 16
White BG000 39 BG001 31 BG002 14 BG003 18 BG004 21 BG005 44 BG006 23 BG007 24 BG008 50 BG009 25 BG010 25 BG011 25 BG012 22 BG013 361
More than one race BG000 0 BG001 0 BG002 0 BG003 0 BG004 0 BG005 0 BG006 0 BG007 1 BG008 0 BG009 0 BG010 0 BG011 0 BG012 0 BG013 1
Unknown or Not Reported BG000 0 BG001 0 BG002 0 BG003 0 BG004 1 BG005 1 BG006 0 BG007 0 BG008 0 BG009 0 BG010 0 BG011 1 BG012 0 BG013 3
OG002 Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Title Denominators Categories Title Measurements OG000 -10.359 ± 9.837 OG001 -5.312 ± 5.796 OG002 -17.540 ± 9.207
OG002 Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Title Denominators Categories Title Measurements OG000 -6.325 ± 7.477 OG001 -4.777 ± 4.765 OG002 -16.959 ± 10.112
OG002 Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Title Denominators Categories Title Measurements OG000 -2.805 ± 4.249 OG001 -1.860 ± 3.844 OG002 -13.346 ± 6.039
Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly
Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18 of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Title Denominators Categories DLT Adverse Event (AE)
Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5of a 28-day cycle in participants with a diagnosis of r/r AML.
OG002 Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5 and 8-12of a 28-day cycle in participants with a diagnosis of r/r AML.
OG003 Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5, SC of a 28-day cycle in participants with a diagnosis of TN AML.
OG004 Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5of a 28-day cycle in participants with a diagnosis of TN AML.
OG005 Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) Participants received guadecitabine 60 mg/m^2, SC, daily, from Days 1-5 and 8-12of a 28-day cycle in participants with a diagnosis of TN AML.
Units Counts Participants OG000 24 OG001 26 OG002 53 OG003 24 OG004 27 OG005 52
Title Denominators Categories Title Measurements OG000 12.5 (2.7 to 32.4) OG001 19.2 (6.6 to 39.4) OG002 30.2 (18.3 to 44.3) OG003 54.2 (32.8 to 74.4) OG004 59.3 (38.8 to 77.6) OG005 50.0 (35.8 to 64.2)
Participants received guadecitabine 90 mg/m^2, SC, daily on Days 1-5of a 28-day cycle in participants with a diagnosis of r/r MDS.
OG002 Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
OG003 Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC. daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
Units Counts Participants OG000 26 OG001 27 OG002 27 OG003 22
Title Denominators Categories Title Measurements OG000 31 (14.3 to 51.8) OG001 56 (35.3 to 74.5) OG002 48 (28.7 to 68.1) OG003 55 (32.2 to 75.6)
Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG002 Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Title Denominators Categories Title Measurements OG000 11.4 (3.2 to 26.7) OG001 7.1 (0.9 to 23.5) OG002 0.0 (0.0 to 28.5)
OG002 Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Title Denominators Categories Title Measurements OG000 22.2 (2.8 to 60.0) OG001 50.0 (11.8 to 88.2) OG002 25.0 (0.6 to 80.6)
Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly
Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG002 Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG003 Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily, from Days 1-5 of a 28-day cycle in participants with diagnosis of r/r AML.
OG004 Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5of a 28-day cycle in participants with a diagnosis of r/r AML.
OG005 Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5 and 8-12of a 28-day cycle in participants with a diagnosis of r/r AML.
OG006 Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5, SC of a 28-day cycle in participants with a diagnosis of TN AML.
OG007 Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5of a 28-day cycle in participants with a diagnosis of TN AML.
OG008 Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) Participants received guadecitabine 60 mg/m^2, SC, daily, from Days 1-5 and 8-12of a 28-day cycle in participants with a diagnosis of TN AML.
Units Counts Participants OG000 4 OG001 2 OG002 0 OG003 3 OG004 5 OG005 16 OG006 13 OG007 16 OG008 26
Title Denominators Categories Title Measurements OG000 213.0 (47 to 350) OG001 300.0 (42 to 558) OG003 816.0 (15 to 880) OG004 112.0 (55 to 879) OG005 233.0 (42 to 898) OG006 237.0 (8 to 1068) OG007 185.5 (16 to 948) OG008 269.5 (40 to 669)
Title Denominators Categories Title Measurements OG000 0.0 (0.0 to 33.6) OG001 50.0 (11.8 to 88.2) OG002 25.0 (0.6 to 80.6)
Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day)
Participants received guadecitabine 90 mg/m^2, SC, daily on Days 1-5of a 28-day cycle in participants with a diagnosis of r/r MDS.
OG002 Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
OG003 Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC. daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
Units Counts Participants OG000 6 OG001 12 OG002 12 OG003 11
Title Denominators Categories CR+PR+mCR Participants OG000 5 Participants OG001 12 Participants OG002 7 Participants OG003 11 Title Measurements OG000 295.0 (101 to 529) OG001 207.0 (42 to 984) OG002 103.0 (35 to 1144) OG003
HI Participants OG000 6 Participants OG001 9 Participants OG002 12 Participants OG003 9
Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG002 Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Title Denominators Categories Title Measurements OG000 106.0 (106 to 147) OG001 55.5 (27 to 84)
Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day)
Participants received guadecitabine 90 mg/m^2, SC, daily on Days 1-5of a 28-day cycle in participants with a diagnosis of r/r MDS.
OG002 Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
OG003 Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC. daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
Units Counts Participants OG000 6 OG001 12 OG002 12 OG003 11
Title Denominators Categories CR+PR+mCR Participants OG000 5 Participants OG001 12 Participants OG002 7 Participants OG003 11 Title Measurements OG000 27.0 (25 to 512) OG001 68.0 (23 to 189) OG002 196.0 (24 to 245) OG003
HI Participants OG000 6 Participants OG001 9 Participants OG002 12 Participants OG003 9
OG001 Dose Escalation: Regimen 2A - Guadecitabine 6 mg/m^2 Once Weekly Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15of a 28-day cycle. The dose was subsequently increased to 18, 36, 60, 90, 125 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG002 Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
Title Denominators Categories
OG002 Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG003 Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily, from Days 1-5 of a 28-day cycle in participants with diagnosis of r/r AML.
OG004 Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5of a 28-day cycle in participants with a diagnosis of r/r AML.
OG005 Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5 and 8-12of a 28-day cycle in participants with a diagnosis of r/r AML.
OG006 Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5, SC of a 28-day cycle in participants with a diagnosis of TN AML.
OG007 Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5of a 28-day cycle in participants with a diagnosis of TN AML.
OG008 Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) Participants received guadecitabine 60 mg/m^2, SC, daily, from Days 1-5 and 8-12of a 28-day cycle in participants with a diagnosis of TN AML.
OG009 Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of r/r MDS.
OG010 Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily on Days 1-5of a 28-day cycle in participants with a diagnosis of r/r MDS.
OG011 Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
OG012 Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC. daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
Units Counts Participants OG000 44 OG001 34 OG002 15 OG003 24 OG004 26 OG005 53 OG006 24 OG007 27 OG008 52 OG009 26 OG010 27 OG011 27 OG012 22
Title Denominators Categories Title Measurements OG000 44 OG001 34 OG002 15 OG003 24 OG004 26 OG005 53 OG006 24 OG007 27 OG008 52 OG009 26 OG010 27 OG011 27 OG012 22
OG003 Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily, from Days 1-5 of a 28-day cycle in participants with diagnosis of r/r AML.
OG004 Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5of a 28-day cycle in participants with a diagnosis of r/r AML.
OG005 Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5 and 8-12of a 28-day cycle in participants with a diagnosis of r/r AML.
OG006 Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5, SC of a 28-day cycle in participants with a diagnosis of TN AML.
OG007 Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5of a 28-day cycle in participants with a diagnosis of TN AML.
OG008 Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) Participants received guadecitabine 60 mg/m^2, SC, daily, from Days 1-5 and 8-12of a 28-day cycle in participants with a diagnosis of TN AML.
OG009 Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of r/r MDS.
OG010 Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily on Days 1-5of a 28-day cycle in participants with a diagnosis of r/r MDS.
OG011 Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
OG012 Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC. daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
Units Counts Participants OG000 44 OG001 34 OG002 15 OG003 24 OG004 26 OG005 53 OG006 24 OG007 27 OG008 52 OG009 26 OG010 27 OG011 27 OG012 22
Title Denominators Categories Alanine Aminotransferase Increased Title Measurements OG000 2 OG001 0 OG002 0 OG003 0 OG004 1 OG005 1 OG006 1 OG007 1 OG008 6 OG009 0 OG010 2 OG011 1 OG012 0
Hypoalbuminaemia Blood Alkaline Phosphatase Increased Blood Alkaline Phosphatase Decreased Aspartate Aminotransferase Increased Blood Creatinine Increased Blood Creatinine Decreased Blood Magnesium Increased Blood Potassium Increased Blood Bilirubin Increased Hyperbilirubinaemia
Participants received starting dose of guadecitabine 36 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG004 Dose Escalation: Regimen 1: Once Daily - SGI-110 - 60 mg/m^2 Participants received starting dose of guadecitabine 60 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG005 Dose Escalation: Regimen 1: Once Daily - 90 mg/m^2 Participants received starting dose of guadecitabine 90 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG006 Dose Escalation: Regimen 1: Once Daily - 125 mg/m^2 Participants received starting dose of guadecitabine 125 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG007 Dose Escalation: Regimen 2A: Once Weekly- 6 mg/m^2 Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15, SC of a 28-day cycle.
OG008 Dose Escalation: Regimen 2A: Once Weekly- 18 mg/m^2 Participants received starting dose of guadecitabine 18 mg/m^2, SC, once weekly on Days 1, 8 and 15, SC of a 28-day cycle.
OG009 Dose Escalation: 10. Regimen 2A: Once Weekly- 36 mg/m^2 Participants received starting dose of guadecitabine 36 mg/m^2, SC, once weekly on Days 1, 8 and 15, SC of a 28-day cycle.
OG010 Dose Escalation: Regimen 2A: Once Weekly - 60 mg/m^2 Participants received starting dose of guadecitabine 60 mg/m^2, SC, once weekly on Days 1, 8 and 15, SC of a 28-day cycle.
OG011 Dose Escalation: Regimen 2A: Once Weekly - 90 mg/m^2 Participants received starting dose of guadecitabine 90 mg/m^2, SC, once weekly on Days 1, 8 and 15, SC of a 28-day cycle.
OG012 Dose Escalation: Regimen 2A: Once Weekly - 125 mg/m^2 Participants received starting dose of guadecitabine 125 mg/m^2, SC, once weekly on Days 1, 8 and 15, SC of a 28-day cycle.
OG013 Dose Escalation: Regimen 2B: Twice Weekly - 60 mg/m^2 Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18 of a 28-day cycle.
Units Counts Participants OG000 4 OG001 4 OG002 5 OG003 6 OG004 7 OG005 6 OG006 12 OG007 6 OG008 3 OG009 6 OG010 4 OG011 7 OG012 6 OG013 7
Title Denominators Categories SGI-110: Day 1 Participants OG000 4 Participants OG001 4 Participants OG002 5 Participants OG003 6 Participants OG004 7 Participants OG005 6 Participants OG006 12 Participants OG007 6 Participants OG008 3 Participants OG009 6 Participants OG010 4 Participants OG011 6 Participants OG012 6 Participants OG013 7 Title Measurements OG000 6.69 ± 72.9 OG001 19.1 ± 43.5 OG002 45.7 ± 57.9 OG003
SGI-110: Day 5 Participants OG000 4 Participants OG001 4 Participants OG002 5 Participants OG003 6 SGI-110: Day 8 Participants OG000 0 Participants OG001 0 Participants OG002 0 Participants OG003 0 Decitabine: Day 1 Participants OG000 4 Participants OG001 4 Participants OG002 5 Participants OG003 6 Decitabine: Day 5 Participants OG000 4 Participants OG001 4 Participants OG002 5 Participants OG003 6 Decitabine: Day 8 Participants OG000 0 Participants OG001 0 Participants OG002 0 Participants OG003 0
Participants received starting dose of guadecitabine 36 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG004 Dose Escalation: Regimen 1: Once Daily - 60 mg/m^2 Participants received starting dose of guadecitabine 60 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG005 Dose Escalation: Regimen 1: Once Daily - 90 mg/m^2 Participants received starting dose of guadecitabine 90 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG006 Dose Escalation: Regimen 1: Once Daily - 125 mg/m^2 Participants received starting dose of guadecitabine 125 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG007 Dose Escalation: Regimen 2A: Once Daily - 6 mg/m^2 Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15, SC of a 28-day cycle.
OG008 Dose Escalation: Regimen 2A: Once Daily - 18 mg/m^2 Participants received starting dose of guadecitabine 18 mg/m^2, SC, once weekly on Days 1, 8 and 15, SC of a 28-day cycle.
OG009 Dose Escalation: Regimen 2A: Once Daily - 36 mg/m^2 Participants received starting dose of guadecitabine 36 mg/m^2, SC, once weekly on Days 1, 8 and 15, SC of a 28-day cycle.
OG010 Dose Escalation: Regimen 2A: Once Daily - 60 mg/m^2 Participants received starting dose of guadecitabine 60 mg/m^2, SC, once weekly on Days 1, 8 and 15, SC of a 28-day cycle.
OG011 Dose Escalation: Regimen 2A: Once Daily - 90 mg/m^2 Participants received starting dose of guadecitabine 90 mg/m^2, SC, once weekly on Days 1, 8 and 15, SC of a 28-day cycle.
OG012 Dose Escalation: Regimen 2A: Once Daily - 125 mg/m^2 Participants received starting dose of guadecitabine 125 mg/m^2, SC, once weekly on Days 1, 8 and 15, SC of a 28-day cycle.
OG013 Dose Escalation: Regimen 2B: Once Daily - 60 mg/m^2 Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18of a 28-day cycle.
Units Counts Participants OG000 4 OG001 4 OG002 5 OG003 6 OG004 7 OG005 6 OG006 12 OG007 5 OG008 3 OG009 6 OG010 4 OG011 8 OG012 6 OG013 0
Title Denominators Categories SGI-110: Day 5 Participants OG000 4 Participants OG001 4 Participants OG002 5 Participants OG003 6 Participants OG004 7 Participants OG005 6 Participants OG006 12 Participants OG007 0 Participants OG008 0 Participants OG009 0 Participants OG010 0 Participants OG011 0 Participants OG012 0 Participants OG013 0 Title Measurements OG000 NA ± NA Data could not be estimable as the values were below lower limit of quantitation (LLOQ) OG001 NA ± NA Data could not be estimable as the values were below LLOQ. OG002 NA ± NA Data could not be estimable as the values were below LLOQ. OG003
SGI-110: Day 8 Participants OG000 0 Participants OG001 0 Participants OG002 0 Participants OG003 0
Participants received starting dose of guadecitabine 36 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG004 Dose Escalation: Regimen 1: Once Daily - SGI-110 - 60 mg/m^2 Participants received starting dose of guadecitabine 60 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG005 Dose Escalation: Regimen 1: Once Daily - 90 mg/m^2 Participants received starting dose of guadecitabine 90 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG006 Dose Escalation: Regimen 1: Once Daily - 125 mg/m^2 Participants received starting dose of guadecitabine 125 mg/m^2, SC, daily from Days 1-5 of a 28-day cycle.
OG007 Dose Escalation: Regimen 2A: Once Daily - 6 mg/m^2 Participants received starting dose of guadecitabine 6 mg/m^2, SC, once weekly on Days 1, 8 and 15, SC of a 28-day cycle.
OG008 Dose Escalation: Regimen 2A: Once Daily - 18 mg/m^2 Participants received starting dose of guadecitabine 18 mg/m^2, SC, once weekly on Days 1, 8 and 15, SC of a 28-day cycle.
OG009 Dose Escalation: 10. Regimen 2A: Once Daily - 36 mg/m^2 Participants received starting dose of guadecitabine 36 mg/m^2, SC, once weekly on Days 1, 8 and 15, SC of a 28-day cycle.
OG010 Dose Escalation: Regimen 2A: Once Daily - 60 mg/m^2 Participants received starting dose of guadecitabine 60 mg/m^2, SC, once weekly on Days 1, 8 and 15, SC of a 28-day cycle.
OG011 Dose Escalation: Regimen 2A: Once Daily - 90 mg/m^2 Participants received starting dose of guadecitabine 90 mg/m^2, SC, once weekly on Days 1, 8 and 15, SC of a 28-day cycle.
OG012 Dose Escalation: Regimen 2A: Once Daily - 125 mg/m^2 Participants received starting dose of guadecitabine 125 mg/m^2, SC, once weekly on Days 1, 8 and 15, SC of a 28-day cycle.
OG013 Dose Escalation: Regimen 2B: Once Daily - 60 mg/m^2 Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18 of a 28-day cycle.
Units Counts Participants OG000 3 OG001 4 OG002 5 OG003 6 OG004 7 OG005 6 OG006 12 OG007 6 OG008 2 OG009 6 OG010 5 OG011 6 OG012 7 OG013 6
Title Denominators Categories SGI-110: Day 1 Participants OG000 3 Participants OG001 4 Participants OG002 5 Participants OG003 5 Participants OG004 7 Participants OG005 6 Participants OG006 12 Participants OG007 6 Participants OG008 2 Participants OG009 6 Participants OG010 5 Participants OG011 6 Participants OG012 6 Participants OG013 6 Title Measurements OG000 12.1 ± 71.5 OG001 45.2 ± 23.9 OG002 102 ± 42.7 OG003
SGI-110: Day 5 Participants OG000 2 Participants OG001 4 Participants OG002 5 Participants OG003 6 SGI-110: Day 8 Participants OG000 0 Participants OG001 0 Participants OG002 0 Participants OG003 0
OG002 Dose Escalation: Regimen 2B - Guadecitabine 60 mg/m^2 Twice Weekly Participants received starting dose of guadecitabine 60 mg/m^2, SC, twice weekly on Days 1, 4, 8, 11, 15 and 18of a 28-day cycle. The dose was subsequently increased to 90 mg/m^2 for subsequent cycles until development of toxicity or disease progression.
OG003 Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of r/r MDS.
OG004 Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily on Days 1-5of a 28-day cycle in participants with a diagnosis of r/r MDS.
OG005 Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
OG006 Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC. daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
Units Counts Participants OG000 44 OG001 35 OG002 15 OG003 26 OG004 27 OG005 27 OG006 22
Title Denominators Categories Title Measurements OG000 244.5 (165.0 to 581.0) OG001 275.0 (197.0 to 585.0) OG002 373.0 (212.0 to NA) Upper limit of full range was not estimable due to insufficient number of participants with events. OG003 273 (164.0 to 622.0) OG004 276 (175.0 to 436.0) OG005 680 (402.0 to 848.0) OG006 542.5 (224.0 to NA) Upper limit of full range was not estimable due to insufficient number of participants with events.
OG003 Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily, from Days 1-5 of a 28-day cycle in participants with diagnosis of r/r AML.
OG004 Dose Expansion: r/r AML Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5of a 28-day cycle in participants with a diagnosis of r/r AML.
OG005 Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day) Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5 and 8-12of a 28-day cycle in participants with a diagnosis of r/r AML.
OG006 Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5, SC of a 28-day cycle in participants with a diagnosis of TN AML.
OG007 Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5of a 28-day cycle in participants with a diagnosis of TN AML.
OG008 Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) Participants received guadecitabine 60 mg/m^2, SC, daily, from Days 1-5 and 8-12of a 28-day cycle in participants with a diagnosis of TN AML.
OG009 Dose Expansion: r/r MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of r/r MDS.
OG010 Dose Expansion: r/r MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily on Days 1-5of a 28-day cycle in participants with a diagnosis of r/r MDS.
OG011 Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
OG012 Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC. daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
Units Counts Participants OG000 44 OG001 35 OG002 15 OG003 50 OG004 53 OG005 0 OG006 0 OG007 0 OG008 0 OG009 26 OG010 27 OG011 27 OG012 22
Title Denominators Categories Title Measurements OG000 124 (82.0 to 181.0) OG001 186.5 (115.0 to 236.0) OG002 212.0 (111.0 to 304.0) OG003 172 (142.0 to 254.0) OG004 214 (169.0 to 269.0) OG009 273 (199.0 to 622.0) OG010 370 (253.0 to 447.0) OG011 771 (460.0 to 1017.0) OG012 558 (269.0 to NA) Upper limit of full range was not estimable due to insufficient number of participants with events.
Title Denominators Categories (Maintaining/achieving platelet transfusion independence) Participants OG000 19 Participants OG001 16 Participants OG002 6 (Maintaining/achieving RBC transfusion independence) Participants OG000 23 Participants OG001 15 Participants OG002 8
Dose Expansion: r/r AML Guadecitabine 60 mg/m^2 (10-Day)
Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5 and 8-12of a 28-day cycle in participants with a diagnosis of r/r AML.
OG003 Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (5-Day) Participants received guadecitabine 60 mg/m^2, SC, daily from Days 1-5, SC of a 28-day cycle in participants with a diagnosis of TN AML.
OG004 Dose Expansion: TN AML Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC, daily, from Days 1-5of a 28-day cycle in participants with a diagnosis of TN AML.
OG005 Dose Expansion: TN AML Guadecitabine 60 mg/m^2 (10-Day) Participants received guadecitabine 60 mg/m^2, SC, daily, from Days 1-5 and 8-12of a 28-day cycle in participants with a diagnosis of TN AML.
Units Counts Participants OG000 24 OG001 26 OG002 53 OG003 24 OG004 27 OG005 52
Title Denominators Categories CR Title Measurements OG000 8.3 OG001 7.7 OG002 18.9 OG003 37.5 OG004 40.7 OG005 32.7
CRi Title Measurements OG000 4.2 OG001 11.5 OG002 3.8 OG003
CRp Title Measurements OG000 0 OG001 0 OG002 7.5 OG003
PR
Dose Expansion: TN MDS Guadecitabine 60 mg/m^2 (5-Day)
Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
OG003 Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC. daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
Units Counts Participants OG000 26 OG001 27 OG002 27 OG003 22
Title Denominators Categories CR+PR+mCR Title Measurements OG000 19 OG001 44 OG002 26 OG003 50
HI Title Measurements OG000 23 OG001 33 OG002 44 OG003
Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
OG003 Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC. daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
Units Counts Participants OG000 16 OG001 18 OG002 15 OG003 9
Title Denominators Categories RBC Independence for Week 8 RBC Independence for Week 16
Participants received guadecitabine 60 mg/m^2, SC, daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
OG003 Dose Expansion: TN MDS Guadecitabine 90 mg/m^2 (5-Day) Participants received guadecitabine 90 mg/m^2, SC. daily on Days 1-5 of a 28-day cycle in participants with a diagnosis of TN MDS.
Units Counts Participants OG000 6 OG001 10 OG002 7 OG003 5
Title Denominators Categories Platelet Independence for Week 8 Platelet Independence for Week 16
5 affected
24 at risk
EG004 9 affected 26 at risk
EG005 17 affected 53 at risk
EG006 4 affected 24 at risk
EG007 10 affected 27 at risk
EG008 16 affected 52 at risk
EG009 4 affected 26 at risk
EG010 10 affected 27 at risk
EG011 7 affected 27 at risk
EG012 4 affected 22 at risk 2 affected
24 at risk
EG004 2 affected 26 at risk
EG005 11 affected 53 at risk
EG006 2 affected 24 at risk
EG007 6 affected 27 at risk
EG008 14 affected 52 at risk
EG009 2 affected 26 at risk
EG010 4 affected 27 at risk
EG011 0 affected 27 at risk
EG012 3 affected 22 at risk 4 affected
24 at risk
EG004 0 affected 26 at risk
EG005 5 affected 53 at risk
EG006 2 affected 24 at risk
EG007 2 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 2 affected 27 at risk
EG011 2 affected 27 at risk
EG012 4 affected 22 at risk 3 affected
24 at risk
EG004 3 affected 26 at risk
EG005 3 affected 53 at risk
EG006 2 affected 24 at risk
EG007 3 affected 27 at risk
EG008 3 affected 52 at risk
EG009 1 affected 26 at risk
EG010 4 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 2 affected 24 at risk
EG007 2 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 3 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 2 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 4 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 2 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 2 affected 27 at risk
EG011 0 affected 27 at risk
EG012 2 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 4 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 3 affected 24 at risk
EG007 1 affected 27 at risk
EG008 2 affected 52 at risk
EG009 2 affected 26 at risk
EG010 2 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 2 affected 26 at risk
EG010 2 affected 27 at risk
EG011 2 affected 27 at risk
EG012 2 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 3 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 2 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 4 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 2 affected 52 at risk
EG009 2 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 2 affected 24 at risk
EG007 2 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 2 affected 24 at risk
EG007 1 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 2 affected 27 at risk
EG011 2 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 2 affected 24 at risk
EG007 2 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 2 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 2 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 3 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 2 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 2 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 2 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 2 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 2 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 8 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 4 affected 52 at risk
EG009 0 affected 26 at risk
EG010 2 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 5 affected 24 at risk
EG007 7 affected 27 at risk
EG008 16 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 2 affected 22 at risk 1 affected
24 at risk
EG004 2 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 3 affected
24 at risk
EG004 4 affected 26 at risk
EG005 4 affected 53 at risk
EG006 6 affected 24 at risk
EG007 6 affected 27 at risk
EG008 2 affected 52 at risk
EG009 2 affected 26 at risk
EG010 4 affected 27 at risk
EG011 5 affected 27 at risk
EG012 4 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 2 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 3 affected
24 at risk
EG004 3 affected 26 at risk
EG005 15 affected 53 at risk
EG006 9 affected 24 at risk
EG007 12 affected 27 at risk
EG008 18 affected 52 at risk
EG009 14 affected 26 at risk
EG010 12 affected 27 at risk
EG011 11 affected 27 at risk
EG012 14 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 6 affected
24 at risk
EG004 5 affected 26 at risk
EG005 26 affected 53 at risk
EG006 13 affected 24 at risk
EG007 12 affected 27 at risk
EG008 24 affected 52 at risk
EG009 14 affected 26 at risk
EG010 14 affected 27 at risk
EG011 9 affected 27 at risk
EG012 12 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 4 affected 53 at risk
EG006 1 affected 24 at risk
EG007 2 affected 27 at risk
EG008 3 affected 52 at risk
EG009 2 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 2 affected
24 at risk
EG004 3 affected 26 at risk
EG005 5 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 2 affected 52 at risk
EG009 2 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 2 affected
24 at risk
EG004 0 affected 26 at risk
EG005 5 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 6 affected 52 at risk
EG009 3 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 2 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 2 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 3 affected
24 at risk
EG004 2 affected 26 at risk
EG005 5 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 3 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 2 affected 26 at risk
EG005 4 affected 53 at risk
EG006 1 affected 24 at risk
EG007 3 affected 27 at risk
EG008 5 affected 52 at risk
EG009 1 affected 26 at risk
EG010 3 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 4 affected
24 at risk
EG004 2 affected 26 at risk
EG005 12 affected 53 at risk
EG006 4 affected 24 at risk
EG007 7 affected 27 at risk
EG008 5 affected 52 at risk
EG009 3 affected 26 at risk
EG010 0 affected 27 at risk
EG011 4 affected 27 at risk
EG012 2 affected 22 at risk 2 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 2 affected 27 at risk
EG008 3 affected 52 at risk
EG009 2 affected 26 at risk
EG010 2 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 5 affected
24 at risk
EG004 9 affected 26 at risk
EG005 22 affected 53 at risk
EG006 12 affected 24 at risk
EG007 14 affected 27 at risk
EG008 32 affected 52 at risk
EG009 5 affected 26 at risk
EG010 6 affected 27 at risk
EG011 10 affected 27 at risk
EG012 12 affected 22 at risk 6 affected
24 at risk
EG004 9 affected 26 at risk
EG005 28 affected 53 at risk
EG006 10 affected 24 at risk
EG007 12 affected 27 at risk
EG008 31 affected 52 at risk
EG009 7 affected 26 at risk
EG010 15 affected 27 at risk
EG011 10 affected 27 at risk
EG012 7 affected 22 at risk 0 affected
24 at risk
EG004 2 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 3 affected 27 at risk
EG008 7 affected 52 at risk
EG009 4 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 2 affected
24 at risk
EG004 4 affected 26 at risk
EG005 6 affected 53 at risk
EG006 1 affected 24 at risk
EG007 3 affected 27 at risk
EG008 5 affected 52 at risk
EG009 3 affected 26 at risk
EG010 7 affected 27 at risk
EG011 2 affected 27 at risk
EG012 2 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 2 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 3 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 2 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 3 affected
24 at risk
EG004 2 affected 26 at risk
EG005 3 affected 53 at risk
EG006 3 affected 24 at risk
EG007 2 affected 27 at risk
EG008 2 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 1 affected
24 at risk
EG004 1 affected 26 at risk
EG005 2 affected 53 at risk
EG006 2 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 3 affected 26 at risk
EG010 1 affected 27 at risk
EG011 2 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 2 affected
24 at risk
EG004 1 affected 26 at risk
EG005 5 affected 53 at risk
EG006 0 affected 24 at risk
EG007 4 affected 27 at risk
EG008 4 affected 52 at risk
EG009 2 affected 26 at risk
EG010 3 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 3 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 1 affected
24 at risk
EG004 1 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 4 affected 27 at risk
EG008 3 affected 52 at risk
EG009 2 affected 26 at risk
EG010 3 affected 27 at risk
EG011 3 affected 27 at risk
EG012 1 affected 22 at risk 6 affected
24 at risk
EG004 5 affected 26 at risk
EG005 31 affected 53 at risk
EG006 11 affected 24 at risk
EG007 13 affected 27 at risk
EG008 26 affected 52 at risk
EG009 10 affected 26 at risk
EG010 8 affected 27 at risk
EG011 8 affected 27 at risk
EG012 12 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 1 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 2 affected 52 at risk
EG009 2 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 3 affected 53 at risk
EG006 1 affected 24 at risk
EG007 3 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 1 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 3 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 4 affected 26 at risk
EG005 19 affected 53 at risk
EG006 4 affected 24 at risk
EG007 9 affected 27 at risk
EG008 15 affected 52 at risk
EG009 2 affected 26 at risk
EG010 11 affected 27 at risk
EG011 3 affected 27 at risk
EG012 7 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 2 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 5 affected
24 at risk
EG004 1 affected 26 at risk
EG005 21 affected 53 at risk
EG006 6 affected 24 at risk
EG007 5 affected 27 at risk
EG008 16 affected 52 at risk
EG009 3 affected 26 at risk
EG010 3 affected 27 at risk
EG011 7 affected 27 at risk
EG012 9 affected 22 at risk 3 affected
24 at risk
EG004 3 affected 26 at risk
EG005 8 affected 53 at risk
EG006 5 affected 24 at risk
EG007 7 affected 27 at risk
EG008 19 affected 52 at risk
EG009 5 affected 26 at risk
EG010 2 affected 27 at risk
EG011 5 affected 27 at risk
EG012 6 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 4 affected 53 at risk
EG006 2 affected 24 at risk
EG007 1 affected 27 at risk
EG008 4 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 2 affected 26 at risk
EG005 5 affected 53 at risk
EG006 2 affected 24 at risk
EG007 3 affected 27 at risk
EG008 6 affected 52 at risk
EG009 0 affected 26 at risk
EG010 2 affected 27 at risk
EG011 1 affected 27 at risk
EG012 6 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 7 affected
24 at risk
EG004 9 affected 26 at risk
EG005 26 affected 53 at risk
EG006 11 affected 24 at risk
EG007 10 affected 27 at risk
EG008 21 affected 52 at risk
EG009 11 affected 26 at risk
EG010 10 affected 27 at risk
EG011 12 affected 27 at risk
EG012 9 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 2 affected 22 at risk 3 affected
24 at risk
EG004 2 affected 26 at risk
EG005 5 affected 53 at risk
EG006 2 affected 24 at risk
EG007 6 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 6 affected 27 at risk
EG011 5 affected 27 at risk
EG012 5 affected 22 at risk 2 affected
24 at risk
EG004 2 affected 26 at risk
EG005 2 affected 53 at risk
EG006 3 affected 24 at risk
EG007 5 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 2 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 2 affected 26 at risk
EG005 5 affected 53 at risk
EG006 2 affected 24 at risk
EG007 5 affected 27 at risk
EG008 6 affected 52 at risk
EG009 1 affected 26 at risk
EG010 4 affected 27 at risk
EG011 8 affected 27 at risk
EG012 4 affected 22 at risk 7 affected
24 at risk
EG004 9 affected 26 at risk
EG005 18 affected 53 at risk
EG006 11 affected 24 at risk
EG007 16 affected 27 at risk
EG008 6 affected 52 at risk
EG009 8 affected 26 at risk
EG010 9 affected 27 at risk
EG011 11 affected 27 at risk
EG012 12 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 6 affected 53 at risk
EG006 2 affected 24 at risk
EG007 2 affected 27 at risk
EG008 7 affected 52 at risk
EG009 3 affected 26 at risk
EG010 1 affected 27 at risk
EG011 4 affected 27 at risk
EG012 4 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 2 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 1 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 2 affected 27 at risk
EG008 3 affected 52 at risk
EG009 2 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 3 affected 53 at risk
EG006 2 affected 24 at risk
EG007 2 affected 27 at risk
EG008 12 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 2 affected 22 at risk 3 affected
24 at risk
EG004 4 affected 26 at risk
EG005 16 affected 53 at risk
EG006 8 affected 24 at risk
EG007 10 affected 27 at risk
EG008 15 affected 52 at risk
EG009 8 affected 26 at risk
EG010 5 affected 27 at risk
EG011 4 affected 27 at risk
EG012 4 affected 22 at risk 0 affected
24 at risk
EG004 2 affected 26 at risk
EG005 5 affected 53 at risk
EG006 5 affected 24 at risk
EG007 2 affected 27 at risk
EG008 13 affected 52 at risk
EG009 1 affected 26 at risk
EG010 2 affected 27 at risk
EG011 1 affected 27 at risk
EG012 2 affected 22 at risk 3 affected
24 at risk
EG004 4 affected 26 at risk
EG005 8 affected 53 at risk
EG006 5 affected 24 at risk
EG007 6 affected 27 at risk
EG008 9 affected 52 at risk
EG009 1 affected 26 at risk
EG010 7 affected 27 at risk
EG011 1 affected 27 at risk
EG012 3 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 1 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 2 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 3 affected 53 at risk
EG006 2 affected 24 at risk
EG007 0 affected 27 at risk
EG008 5 affected 52 at risk
EG009 2 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 4 affected 53 at risk
EG006 0 affected 24 at risk
EG007 2 affected 27 at risk
EG008 4 affected 52 at risk
EG009 0 affected 26 at risk
EG010 2 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 3 affected
24 at risk
EG004 3 affected 26 at risk
EG005 8 affected 53 at risk
EG006 3 affected 24 at risk
EG007 3 affected 27 at risk
EG008 14 affected 52 at risk
EG009 1 affected 26 at risk
EG010 2 affected 27 at risk
EG011 4 affected 27 at risk
EG012 5 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 2 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 2 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 3 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 2 affected 27 at risk
EG011 2 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 2 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 2 affected 26 at risk
EG005 6 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 3 affected 52 at risk
EG009 1 affected 26 at risk
EG010 2 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 2 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 2 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 2 affected
24 at risk
EG004 2 affected 26 at risk
EG005 15 affected 53 at risk
EG006 3 affected 24 at risk
EG007 5 affected 27 at risk
EG008 8 affected 52 at risk
EG009 3 affected 26 at risk
EG010 5 affected 27 at risk
EG011 2 affected 27 at risk
EG012 2 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 1 affected 26 at risk
EG005 4 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 3 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 events 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 1 affected 26 at risk
EG005 3 affected 53 at risk
EG006 1 affected 24 at risk
EG007 4 affected 27 at risk
EG008 4 affected 52 at risk
EG009 1 affected 26 at risk
EG010 5 affected 27 at risk
EG011 4 affected 27 at risk
EG012 4 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 8 affected 53 at risk
EG006 3 affected 24 at risk
EG007 2 affected 27 at risk
EG008 6 affected 52 at risk
EG009 1 affected 26 at risk
EG010 3 affected 27 at risk
EG011 3 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 8 affected 53 at risk
EG006 8 affected 24 at risk
EG007 5 affected 27 at risk
EG008 11 affected 52 at risk
EG009 9 affected 26 at risk
EG010 5 affected 27 at risk
EG011 7 affected 27 at risk
EG012 6 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 2 affected 24 at risk
EG007 2 affected 27 at risk
EG008 1 affected 52 at risk
EG009 2 affected 26 at risk
EG010 2 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 5 affected 53 at risk
EG006 2 affected 24 at risk
EG007 2 affected 27 at risk
EG008 10 affected 52 at risk
EG009 4 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 2 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 2 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 3 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 6 affected 52 at risk
EG009 0 affected 26 at risk
EG010 2 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 2 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 3 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 2 affected 26 at risk
EG005 4 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 3 affected 27 at risk
EG008 2 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 3 affected 53 at risk
EG006 2 affected 24 at risk
EG007 2 affected 27 at risk
EG008 4 affected 52 at risk
EG009 0 affected 26 at risk
EG010 2 affected 27 at risk
EG011 2 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 4 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 7 affected 53 at risk
EG006 5 affected 24 at risk
EG007 1 affected 27 at risk
EG008 3 affected 52 at risk
EG009 3 affected 26 at risk
EG010 2 affected 27 at risk
EG011 3 affected 27 at risk
EG012 2 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 4 affected
24 at risk
EG004 6 affected 26 at risk
EG005 25 affected 53 at risk
EG006 8 affected 24 at risk
EG007 14 affected 27 at risk
EG008 20 affected 52 at risk
EG009 8 affected 26 at risk
EG010 8 affected 27 at risk
EG011 4 affected 27 at risk
EG012 7 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 2 affected 27 at risk
EG008 3 affected 52 at risk
EG009 2 affected 26 at risk
EG010 2 affected 27 at risk
EG011 1 affected 27 at risk
EG012 5 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 3 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 2 affected
24 at risk
EG004 1 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 5 affected 27 at risk
EG008 3 affected 52 at risk
EG009 0 affected 26 at risk
EG010 2 affected 27 at risk
EG011 3 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 1 affected 26 at risk
EG005 3 affected 53 at risk
EG006 2 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 2 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 4 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 3 affected
24 at risk
EG004 6 affected 26 at risk
EG005 4 affected 53 at risk
EG006 2 affected 24 at risk
EG007 1 affected 27 at risk
EG008 3 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 2 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 2 affected 26 at risk
EG005 0 affected 53 at risk
EG006 2 affected 24 at risk
EG007 1 affected 27 at risk
EG008 3 affected 52 at risk
EG009 2 affected 26 at risk
EG010 2 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 7 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 3 affected 52 at risk
EG009 0 affected 26 at risk
EG010 2 affected 27 at risk
EG011 2 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 3 affected 24 at risk
EG007 3 affected 27 at risk
EG008 4 affected 52 at risk
EG009 0 affected 26 at risk
EG010 2 affected 27 at risk
EG011 3 affected 27 at risk
EG012 1 affected 22 at risk 9 affected
24 at risk
EG004 11 affected 26 at risk
EG005 25 affected 53 at risk
EG006 9 affected 24 at risk
EG007 14 affected 27 at risk
EG008 27 affected 52 at risk
EG009 2 affected 26 at risk
EG010 8 affected 27 at risk
EG011 6 affected 27 at risk
EG012 6 affected 22 at risk 4 affected
24 at risk
EG004 8 affected 26 at risk
EG005 27 affected 53 at risk
EG006 6 affected 24 at risk
EG007 8 affected 27 at risk
EG008 23 affected 52 at risk
EG009 4 affected 26 at risk
EG010 4 affected 27 at risk
EG011 9 affected 27 at risk
EG012 4 affected 22 at risk 0 affected
24 at risk
EG004 2 affected 26 at risk
EG005 5 affected 53 at risk
EG006 3 affected 24 at risk
EG007 3 affected 27 at risk
EG008 8 affected 52 at risk
EG009 1 affected 26 at risk
EG010 3 affected 27 at risk
EG011 6 affected 27 at risk
EG012 3 affected 22 at risk 4 affected
24 at risk
EG004 4 affected 26 at risk
EG005 5 affected 53 at risk
EG006 2 affected 24 at risk
EG007 6 affected 27 at risk
EG008 6 affected 52 at risk
EG009 1 affected 26 at risk
EG010 2 affected 27 at risk
EG011 2 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 6 affected 53 at risk
EG006 3 affected 24 at risk
EG007 4 affected 27 at risk
EG008 8 affected 52 at risk
EG009 5 affected 26 at risk
EG010 2 affected 27 at risk
EG011 4 affected 27 at risk
EG012 3 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 2 affected
24 at risk
EG004 1 affected 26 at risk
EG005 10 affected 53 at risk
EG006 6 affected 24 at risk
EG007 3 affected 27 at risk
EG008 12 affected 52 at risk
EG009 2 affected 26 at risk
EG010 3 affected 27 at risk
EG011 6 affected 27 at risk
EG012 2 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 5 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 3 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 5 affected 53 at risk
EG006 2 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 1 affected
24 at risk
EG004 1 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 3 affected 52 at risk
EG009 3 affected 26 at risk
EG010 2 affected 27 at risk
EG011 5 affected 27 at risk
EG012 1 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 1 affected 24 at risk
EG007 4 affected 27 at risk
EG008 3 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 5 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 3 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 4 affected 53 at risk
EG006 2 affected 24 at risk
EG007 2 affected 27 at risk
EG008 3 affected 52 at risk
EG009 2 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 2 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 6 affected 53 at risk
EG006 3 affected 24 at risk
EG007 0 affected 27 at risk
EG008 4 affected 52 at risk
EG009 7 affected 26 at risk
EG010 3 affected 27 at risk
EG011 3 affected 27 at risk
EG012 1 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 3 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 2 affected
24 at risk
EG004 2 affected 26 at risk
EG005 5 affected 53 at risk
EG006 2 affected 24 at risk
EG007 3 affected 27 at risk
EG008 7 affected 52 at risk
EG009 2 affected 26 at risk
EG010 3 affected 27 at risk
EG011 8 affected 27 at risk
EG012 5 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 6 affected 24 at risk
EG007 8 affected 27 at risk
EG008 14 affected 52 at risk
EG009 7 affected 26 at risk
EG010 5 affected 27 at risk
EG011 5 affected 27 at risk
EG012 4 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 5 affected 24 at risk
EG007 1 affected 27 at risk
EG008 3 affected 52 at risk
EG009 1 affected 26 at risk
EG010 4 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 5 affected
24 at risk
EG004 3 affected 26 at risk
EG005 13 affected 53 at risk
EG006 6 affected 24 at risk
EG007 6 affected 27 at risk
EG008 8 affected 52 at risk
EG009 4 affected 26 at risk
EG010 6 affected 27 at risk
EG011 3 affected 27 at risk
EG012 7 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 3 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 4 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 3 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 2 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 3 affected 53 at risk
EG006 2 affected 24 at risk
EG007 1 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 3 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 3 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 2 affected 26 at risk
EG005 8 affected 53 at risk
EG006 2 affected 24 at risk
EG007 1 affected 27 at risk
EG008 14 affected 52 at risk
EG009 3 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 2 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 11 affected 53 at risk
EG006 5 affected 24 at risk
EG007 3 affected 27 at risk
EG008 5 affected 52 at risk
EG009 3 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 3 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 4 affected
24 at risk
EG004 2 affected 26 at risk
EG005 10 affected 53 at risk
EG006 6 affected 24 at risk
EG007 5 affected 27 at risk
EG008 6 affected 52 at risk
EG009 6 affected 26 at risk
EG010 6 affected 27 at risk
EG011 5 affected 27 at risk
EG012 8 affected 22 at risk 3 affected
24 at risk
EG004 1 affected 26 at risk
EG005 6 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 2 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 2 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 2 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 6 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 2 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 3 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 2 affected 24 at risk
EG007 2 affected 27 at risk
EG008 2 affected 52 at risk
EG009 4 affected 26 at risk
EG010 1 affected 27 at risk
EG011 2 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 2 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 1 affected 26 at risk
EG005 3 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 3 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 2 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 2 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 6 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 2 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 4 affected
24 at risk
EG004 7 affected 26 at risk
EG005 22 affected 53 at risk
EG006 9 affected 24 at risk
EG007 6 affected 27 at risk
EG008 20 affected 52 at risk
EG009 8 affected 26 at risk
EG010 10 affected 27 at risk
EG011 7 affected 27 at risk
EG012 5 affected 22 at risk 6 affected
24 at risk
EG004 4 affected 26 at risk
EG005 9 affected 53 at risk
EG006 6 affected 24 at risk
EG007 12 affected 27 at risk
EG008 26 affected 52 at risk
EG009 4 affected 26 at risk
EG010 6 affected 27 at risk
EG011 6 affected 27 at risk
EG012 7 affected 22 at risk 4 affected
24 at risk
EG004 6 affected 26 at risk
EG005 8 affected 53 at risk
EG006 3 affected 24 at risk
EG007 7 affected 27 at risk
EG008 13 affected 52 at risk
EG009 6 affected 26 at risk
EG010 7 affected 27 at risk
EG011 5 affected 27 at risk
EG012 2 affected 22 at risk 0 affected
24 at risk
EG004 2 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 3 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 5 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 3 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 8 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 3 affected 52 at risk
EG009 3 affected 26 at risk
EG010 6 affected 27 at risk
EG011 3 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 3 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 3 affected
24 at risk
EG004 3 affected 26 at risk
EG005 9 affected 53 at risk
EG006 2 affected 24 at risk
EG007 5 affected 27 at risk
EG008 13 affected 52 at risk
EG009 2 affected 26 at risk
EG010 3 affected 27 at risk
EG011 4 affected 27 at risk
EG012 4 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 2 affected
24 at risk
EG004 3 affected 26 at risk
EG005 1 affected 53 at risk
EG006 2 affected 24 at risk
EG007 1 affected 27 at risk
EG008 8 affected 52 at risk
EG009 1 affected 26 at risk
EG010 2 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 3 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 2 affected 27 at risk
EG011 1 affected 27 at risk
EG012 2 affected 22 at risk 1 affected
24 at risk
EG004 1 affected 26 at risk
EG005 4 affected 53 at risk
EG006 1 affected 24 at risk
EG007 2 affected 27 at risk
EG008 7 affected 52 at risk
EG009 4 affected 26 at risk
EG010 3 affected 27 at risk
EG011 2 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 3 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 3 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 1 affected
24 at risk
EG004 1 affected 26 at risk
EG005 2 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 4 affected 53 at risk
EG006 0 affected 24 at risk
EG007 3 affected 27 at risk
EG008 1 affected 52 at risk
EG009 2 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 1 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 4 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 2 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 2 affected 27 at risk
EG008 5 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 4 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 4 affected 53 at risk
EG006 0 affected 24 at risk
EG007 3 affected 27 at risk
EG008 11 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 2 affected 27 at risk
EG012 3 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 3 affected 53 at risk
EG006 3 affected 24 at risk
EG007 2 affected 27 at risk
EG008 9 affected 52 at risk
EG009 3 affected 26 at risk
EG010 3 affected 27 at risk
EG011 1 affected 27 at risk
EG012 2 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 3 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 4 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 2 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 1 affected
24 at risk
EG004 2 affected 26 at risk
EG005 4 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 8 affected 52 at risk
EG009 2 affected 26 at risk
EG010 3 affected 27 at risk
EG011 2 affected 27 at risk
EG012 5 affected 22 at risk 3 affected
24 at risk
EG004 1 affected 26 at risk
EG005 6 affected 53 at risk
EG006 2 affected 24 at risk
EG007 5 affected 27 at risk
EG008 5 affected 52 at risk
EG009 6 affected 26 at risk
EG010 4 affected 27 at risk
EG011 5 affected 27 at risk
EG012 3 affected 22 at risk 1 affected
24 at risk
EG004 1 affected 26 at risk
EG005 3 affected 53 at risk
EG006 3 affected 24 at risk
EG007 0 affected 27 at risk
EG008 6 affected 52 at risk
EG009 1 affected 26 at risk
EG010 2 affected 27 at risk
EG011 2 affected 27 at risk
EG012 4 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 2 affected 26 at risk
EG005 11 affected 53 at risk
EG006 1 affected 24 at risk
EG007 4 affected 27 at risk
EG008 11 affected 52 at risk
EG009 2 affected 26 at risk
EG010 4 affected 27 at risk
EG011 9 affected 27 at risk
EG012 5 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 2 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 2 affected
24 at risk
EG004 1 affected 26 at risk
EG005 3 affected 53 at risk
EG006 3 affected 24 at risk
EG007 1 affected 27 at risk
EG008 5 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 2 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 3 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 2 affected 26 at risk
EG010 2 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 5 affected 27 at risk
EG008 2 affected 52 at risk
EG009 2 affected 26 at risk
EG010 1 affected 27 at risk
EG011 2 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 2 affected 26 at risk
EG005 5 affected 53 at risk
EG006 1 affected 24 at risk
EG007 2 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 2 affected 22 at risk 4 affected
24 at risk
EG004 5 affected 26 at risk
EG005 10 affected 53 at risk
EG006 3 affected 24 at risk
EG007 3 affected 27 at risk
EG008 10 affected 52 at risk
EG009 3 affected 26 at risk
EG010 4 affected 27 at risk
EG011 2 affected 27 at risk
EG012 2 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 2 affected
24 at risk
EG004 11 affected 26 at risk
EG005 13 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 2 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 4 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 2 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 3 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 2 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 2 affected 26 at risk
EG010 2 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 2 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 1 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 3 affected 27 at risk
EG008 3 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 3 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 2 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 2 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 2 affected 22 at risk 1 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 2 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 2 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 2 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 3 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 2 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 2 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 3 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 3 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 4 affected 53 at risk
EG006 1 affected 24 at risk
EG007 2 affected 27 at risk
EG008 5 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 3 affected
24 at risk
EG004 2 affected 26 at risk
EG005 3 affected 53 at risk
EG006 3 affected 24 at risk
EG007 1 affected 27 at risk
EG008 10 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 2 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 3 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 2 affected 27 at risk
EG011 2 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 3 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 2 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 1 affected 26 at risk
EG010 2 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 2 affected
24 at risk
EG004 4 affected 26 at risk
EG005 10 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 6 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 2 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 3 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 2 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 2 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 2 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 2 affected 27 at risk
EG008 3 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 3 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 2 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 2 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 1 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 3 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 1 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 3 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 2 affected 26 at risk
EG010 0 affected 27 at risk
EG011 2 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 2 affected 26 at risk
EG005 2 affected 53 at risk
EG006 2 affected 24 at risk
EG007 1 affected 27 at risk
EG008 5 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 3 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 2 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 2 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 3 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 1 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 2 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 3 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 2 affected 24 at risk
EG007 6 affected 27 at risk
EG008 10 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 2 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 2 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 2 affected 27 at risk
EG008 2 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 2 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 1 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 1 affected 24 at risk
EG007 1 affected 27 at risk
EG008 1 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 2 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 2 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 1 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 1 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 0 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 0 affected 26 at risk
EG010 0 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 0 affected
24 at risk
EG004 0 affected 26 at risk
EG005 0 affected 53 at risk
EG006 0 affected 24 at risk
EG007 0 affected 27 at risk
EG008 0 affected 52 at risk
EG009 1 affected 26 at risk
EG010 2 affected 27 at risk
EG011 0 affected 27 at risk
EG012 1 affected 22 at risk 165.0
(42 to 958)
Title Measurements OG000 202.5 (91 to 574) OG001 193.0 (71 to 1050) OG002 227.0 (89 to 525) OG003 127.0 (81 to 1087)
133
(47 to 392)
Title Measurements OG000 108.0 (5 to 173) OG001 58.0 (27 to 277) OG002 64.5 (0 to 364) OG003 49.0 (27 to 119)
0
OG004 1
OG005 1
OG006 1
OG007 1
OG008 3
OG009 0
OG010 2
OG011 2
OG012 1 0
OG004 2
OG005 2
OG006 1
OG007 0
OG008 1
OG009 0
OG010 0
OG011 0
OG012 0 0
OG004 0
OG005 0
OG006 0
OG007 0
OG008 0
OG009 0
OG010 0
OG011 0
OG012 0 0
OG004 1
OG005 1
OG006 1
OG007 1
OG008 3
OG009 0
OG010 0
OG011 1
OG012 1 0
OG004 1
OG005 1
OG006 2
OG007 2
OG008 4
OG009 0
OG010 2
OG011 2
OG012 1 0
OG004 0
OG005 0
OG006 0
OG007 0
OG008 0
OG009 0
OG010 0
OG011 0
OG012 0 0
OG004 0
OG005 0
OG006 0
OG007 0
OG008 0
OG009 0
OG010 0
OG011 0
OG012 0 0
OG004 0
OG005 0
OG006 0
OG007 0
OG008 0
OG009 0
OG010 0
OG011 0
OG012 0 0
OG004 0
OG005 0
OG006 0
OG007 3
OG008 2
OG009 1
OG010 0
OG011 1
OG012 0 1
OG004 1
OG005 2
OG006 0
OG007 0
OG008 1
OG009 1
OG010 1
OG011 0
OG012 0 106
± 129
OG004 121 ± 31.9
OG005 155 ± 34.6
OG006 178 ± 46.2
OG007 11.7 ± 65.7
OG008 37.4 ± 73.4
OG009 61.9 ± 44.5
OG010 101 ± 51.0
OG011 100 ± 30.2
OG012 219 ± 36.5
OG013 106 ± 29.9 Participants
OG004
5
Participants OG005 6
Participants OG006 11
Participants OG007 0
Participants OG008 0
Participants OG009 0
Participants OG010 0
Participants OG011 0
Participants OG012 0
Participants OG013 0 Title Measurements OG000 11.1 ± 65.8 OG001 30.7 ± 42.5 OG002 45.2 ± 43.4 OG003 72.7 ± 41.1 OG004 120 ± 31.7 OG005 205 ± 34.9 OG006 173 ± 36.7
Participants
OG004
0
Participants OG005 0
Participants OG006 0
Participants OG007 5
Participants OG008 3
Participants OG009 6
Participants OG010 4
Participants OG011 7
Participants OG012 6
Participants OG013 0 Title Measurements OG007 10.7 ± 60.7 OG008 18.1 ± 99.3 OG009 66.3 ± 63.8 OG010 107 ± 40.0 OG011 118 ± 27.8 OG012 187 ± 40.9
Participants OG004 7
Participants OG005 6
Participants OG006 12
Participants OG007 6
Participants OG008 3
Participants OG009 6
Participants OG010 4
Participants OG011 6
Participants OG012 6
Participants OG013 7 Title Measurements OG000 1.27 ± 30.5 OG001 2.54 ± 18.5 OG002 8.18 ± 56.9 OG003 13.9 ± 60.4 OG004 23.7 ± 79.8 OG005 42.0 ± 40.0 OG006 61.5 ± 37.4 OG007 3.05 ± 48.4 OG008 8.20 ± 52.7 OG009 17.1 ± 55.9 OG010 16.7 ± 47.0 OG011 30.1 ± 41.3 OG012 65.9 ± 50.0 OG013 26.1 ± 83.2
Participants OG004 5
Participants OG005 6
Participants OG006 11
Participants OG007 0
Participants OG008 0
Participants OG009 0
Participants OG010 0
Participants OG011 0
Participants OG012 0
Participants OG013 0 Title Measurements OG000 1.67 ± 54.7 OG001 3.52 ± 27.4 OG002 10.3 ± 65.1 OG003 16.7 ± 37.6 OG004 22.7 ± 69.9 OG005 53.6 ± 37.4 OG006 59.1 ± 30.5
Participants OG004 0
Participants OG005 0
Participants OG006 0
Participants OG007 5
Participants OG008 3
Participants OG009 6
Participants OG010 4
Participants OG011 7
Participants OG012 6
Participants OG013 0 Title Measurements OG007 2.78 ± 43.8 OG008 6.92 ± 79.5 OG009 12.7 ± 41.8 OG010 19.0 ± 55.8 OG011 35.0 ± 45.4 OG012 53.2 ± 39.5
NA
± NA
Data could not be estimable as the values were below LLOQ.
OG004 NA ± NA Data could not be estimable as the values were below LLOQ.
OG005 NA ± NA Data could not be estimable as the values were below LLOQ.
OG006 NA ± NA Data could not be estimable as the values were below LLOQ. Participants
OG004
0
Participants OG005 0
Participants OG006 0
Participants OG007 5
Participants OG008 3
Participants OG009 6
Participants OG010 4
Participants OG011 8
Participants OG012 6
Participants OG013 0 Title Measurements OG007 NA ± 224 Data could not be estimable as the values were below LLOQ. OG008 NA ± NA Data could not be estimable as the values were below LLOQ. OG009 NA ± NA Data could not be estimable as the values were below LLOQ. OG010 NA ± 200 Data could not be estimable as the values were below LLOQ. OG011 NA ± NA Data could not be estimable as the values were below LLOQ. OG012 NA ± NA Data could not be estimable as the values were below LLOQ.
211
± 55.8
OG004 410 ± 25.8
OG005 528 ± 26.8
OG006 648 ± 31.3
OG007 21.4 ± 65.4
OG008 99.8 ± 25.2
OG009 182 ± 19.5
OG010 327 ± 48.9
OG011 331 ± 23.1
OG012 636 ± 40.2
OG013 328 ± 38.4 Participants
OG004
5
Participants OG005 6
Participants OG006 11
Participants OG007 0
Participants OG008 0
Participants OG009 0
Participants OG010 0
Participants OG011 0
Participants OG012 0
Participants OG013 0 Title Measurements OG000 26.5 ± 5.87 OG001 63.5 ± 13.7 OG002 112 ± 29.8 OG003 226 ± 35.0 OG004 354 ± 13.8 OG005 423 ± 46.0 OG006 658 ± 26.9
Participants
OG004
0
Participants OG005 0
Participants OG006 0
Participants OG007 5
Participants OG008 2
Participants OG009 5
Participants OG010 4
Participants OG011 6
Participants OG012 7
Participants OG013 0 Title Measurements OG007 17.9 ± 42.1 OG008 58.0 ± 15.0 OG009 227 ± 50.5 OG010 371 ± 15.2 OG011 383 ± 27.4 OG012 675 ± 45.1
100
OG001 79
OG002 89 16.7
OG004 11.1
OG005 7.7 0
OG004 7.4
OG005 9.6 4.2
OG004 3.7
OG005 1.9 41
1
2